

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number
WO 01/57085 A2

- (51) International Patent Classification⁷: **C07K 14/705**, 16/28, C12N 5/10, C12Q 1/68, A61K 38/17, A01K 67/027, G01N 33/53
- (74) Agents: **HAMLET-COX, Diana et al.**; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).
- (21) International Application Number: PCT/US01/03455
- (22) International Filing Date: 1 February 2001 (01.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/180,093 2 February 2000 (02.02.2000) US
60/182,045 11 February 2000 (11.02.2000) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **AU-YOUNG, Janice** [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/57085 A2

(54) Title: G-PROTEIN COUPLED RECEPTORS

(57) Abstract: The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

G-PROTEIN COUPLED RECEPTORS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of G-protein coupled receptors and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.

BACKGROUND OF THE INVENTION

Signal transduction is the general process by which cells respond to extracellular signals. Signal transduction across the plasma membrane begins with the binding of a signal molecule, e.g., a hormone, neurotransmitter, or growth factor, to a cell membrane receptor. The receptor, thus activated, triggers an intracellular biochemical cascade that ends with the activation of an intracellular target molecule, such as a transcription factor. This process of signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription. The G-protein coupled receptors (GPCRs), encoded by one of the largest families of genes yet identified, play a central role in the transduction of extracellular signals across the plasma membrane. GPCRs have a proven history of being successful therapeutic targets.

GPCRs are integral membrane proteins characterized by the presence of seven hydrophobic transmembrane domains which together form a bundle of antiparallel alpha (α) helices. GPCRs range in size from under 400 to over 1000 amino acids (Strosberg, A.D. (1991) Eur. J. Biochem. 196:1-10; Coughlin, S.R. (1994) Curr. Opin. Cell Biol. 6:191-197). The amino-terminus of a GPCR is extracellular, is of variable length, and is often glycosylated. The carboxy-terminus is cytoplasmic and generally phosphorylated. Extracellular loops alternate with intracellular loops and link the transmembrane domains. Cysteine disulfide bridges linking the second and third extracellular loops may interact with agonists and antagonists. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. The transmembrane domains account, in part, for structural and functional features of the receptor. In most cases, the bundle of α helices forms a ligand-binding pocket. The extracellular N-terminal segment, or one or more of the three extracellular loops, may also participate in ligand binding. Ligand binding activates the receptor by inducing a conformational change in intracellular portions of the receptor. In turn, the large, third intracellular loop of the activated receptor interacts with a heterotrimeric guanine nucleotide binding (G) protein complex which mediates further intracellular signaling activities, including the activation of second

messengers such as cyclic AMP (cAMP), phospholipase C, and inositol triphosphate, and the interaction of the activated GPCR with ion channel proteins. (See, e.g., Watson, S. and S. Arkininstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6; Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego CA, pp. 162-176; Baldwin, J.M. (1994) *Curr. Opin. Cell Biol.* 6:180-190.)

GPCRs include receptors for sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine, γ -aminobutyric acid (GABA), hepatocyte growth factor, melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive intestinal polypeptide family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine and norepinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin); chemokines; lipid mediators of inflammation (e.g., prostaglandins and prostanoids, platelet activating factor, and leukotrienes); and peptide hormones (e.g., bombesin, bradykinin, calcitonin, C5a anaphylatoxin, endothelin, follicle-stimulating hormone (FSH), gonadotropic-releasing hormone (GnRH), neurokinin, and thyrotropin-releasing hormone (TRH), and oxytocin). GPCRs which act as receptors for stimuli that have yet to be identified are known as orphan receptors.

The diversity of the GPCR family is further increased by alternative splicing. Many GPCR genes contain introns, and there are currently over 30 such receptors for which splice variants have been identified. The largest number of variations are at the protein C-terminus. N-terminal and cytoplasmic loop variants are also frequent, while variants in the extracellular loops or transmembrane domains are less common. Some receptors have more than one site at which variance can occur. The splicing variants appear to be functionally distinct, based upon observed differences in distribution, signaling, coupling, regulation, and ligand binding profiles (Kilpatrick, G.J. et al. (1999) *Trends Pharmacol. Sci.* 20:294-301).

GPCRs can be divided into three major subfamilies: the rhodopsin-like, secretin-like, and metabotropic glutamate receptor subfamilies. Members of these GPCR subfamilies share similar functions and the characteristic seven transmembrane structure, but have divergent amino acid sequences. The largest family consists of the rhodopsin-like GPCRs, which transmit diverse extracellular signals including hormones, neurotransmitters, and light. Rhodopsin is a photosensitive GPCR found in animal retinas. In vertebrates, rhodopsin molecules are embedded in membranous stacks found in photoreceptor (rod) cells. Each rhodopsin molecule responds to a photon of light by triggering a decrease in cGMP levels which leads to the closure of plasma membrane sodium channels. In this manner, a visual signal is converted to a neural impulse. Other rhodopsin-like GPCRs are directly involved in responding to neurotransmitters. These GPCRs include the receptors for adrenaline (adrenergic receptors), acetylcholine (muscarinic receptors), adenosine, galanin, and glutamate (N-

methyl-D-aspartate/NMDA receptors). (Reviewed in Watson, S. and S. Arkinstall (1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 7-9, 19-22, 32-35, 130-131, 214-216, 221-222; Habert-Ortoli, E. et al. (1994) Proc. Natl. Acad. Sci. USA 91:9780-9783.)

The galanin receptors mediate the activity of the neuroendocrine peptide galanin, which
5 inhibits secretion of insulin, acetylcholine, serotonin and noradrenaline, and stimulates prolactin and growth hormone release. Galanin receptors are involved in feeding disorders, pain, depression, and Alzheimer's disease (Kask, K. et al. (1997) Life Sci. 60:1523-1533). Other nervous system rhodopsin-like GPCRs include a growing family of receptors for lysophosphatidic acid and other
10 lysophospholipids, which appear to have roles in development and neuropathology (Chun, J. et al. (1999) Cell Biochem. Biophys. 30:213-242).

The largest subfamily of GPCRs, the olfactory receptors, are also members of the rhodopsin-like GPCR family. These receptors function by transducing odorant signals. Numerous distinct olfactory receptors are required to distinguish different odors. Each olfactory sensory neuron expresses only one type of olfactory receptor, and distinct spatial zones of neurons expressing distinct receptors
15 are found in nasal passages. For example, the RA1c receptor which was isolated from a rat brain library, has been shown to be limited in expression to very distinct regions of the brain and a defined zone of the olfactory epithelium (Raming, K. et al. (1998) Receptors Channels 6:141-151). However, the expression of olfactory-like receptors is not confined to olfactory tissues. For example, three rat genes encoding olfactory-like receptors having typical GPCR characteristics showed expression
20 patterns not only in taste and olfactory tissue, but also in male reproductive tissue (Thomas, M.B. et al. (1996) Gene 178:1-5).

Members of the secretin-like GPCR subfamily have as their ligands peptide hormones such as secretin, calcitonin, glucagon, growth hormone-releasing hormone, parathyroid hormone, and vasoactive intestinal peptide. For example, the secretin receptor responds to secretin, a peptide
25 hormone that stimulates the secretion of enzymes and ions in the pancreas and small intestine (Watson, supra, pp. 278-283). Secretin receptors are about 450 amino acids in length and are found in the plasma membrane of gastrointestinal cells. Binding of secretin to its receptor stimulates the production of cAMP.

Examples of secretin-like GPCRs implicated in inflammation and the immune response
30 include the EGF module-containing, mucin-like hormone receptor (Emr1) and CD97 receptor proteins. These GPCRs are members of the recently characterized EGF-TM7 receptors subfamily. These seven transmembrane hormone receptors exist as heterodimers in vivo and contain between three and seven potential calcium-binding EGF-like motifs. CD97 is predominantly expressed in leukocytes and is markedly upregulated on activated B and T cells (McKnight, A.J. and S. Gordon

(1998) J. Leukoc. Biol. 63:271-280).

The third GPCR subfamily is the metabotropic glutamate receptor family. Glutamate is the major excitatory neurotransmitter in the central nervous system. The metabotropic glutamate receptors modulate the activity of intracellular effectors, and are involved in long-term potentiation (Watson, *supra*, p.130). The Ca^{2+} -sensing receptor, which senses changes in the extracellular concentration of calcium ions, has a large extracellular domain including clusters of acidic amino acids which may be involved in calcium binding. The metabotropic glutamate receptor family also includes pheromone receptors, the GABA_B receptors, and the taste receptors.

Other subfamilies of GPCRs include two groups of chemoreceptor genes found in the nematodes Caenorhabditis elegans and Caenorhabditis briggsae, which are distantly related to the mammalian olfactory receptor genes. The yeast pheromone receptors STE2 and STE3, involved in the response to mating factors on the cell membrane, have their own seven-transmembrane signature, as do the cAMP receptors from the slime mold Dictyostelium discoideum, which are thought to regulate the aggregation of individual cells and control the expression of numerous developmentally-regulated genes.

GPCR mutations, which may cause loss of function or constitutive activation, have been associated with numerous human diseases (Coughlin, *supra*). For instance, retinitis pigmentosa may arise from mutations in the rhodopsin gene. Furthermore, somatic activating mutations in the thyrotropin receptor have been reported to cause hyperfunctioning thyroid adenomas, suggesting that certain GPCRs susceptible to constitutive activation may behave as protooncogenes (Parma, J. et al. (1993) Nature 365:649-651). GPCR receptors for the following ligands also contain mutations associated with human disease: luteinizing hormone (precocious puberty); vasopressin V_2 (X-linked nephrogenic diabetes); glucagon (diabetes and hypertension); calcium (hyperparathyroidism, hypocalcuria, hypercalcemia); parathyroid hormone (short limbed dwarfism); β_3 -adrenoceptor (obesity, non-insulin-dependent diabetes mellitus); growth hormone releasing hormone (dwarfism); and adrenocorticotropin (glucocorticoid deficiency) (Wilson, S. et al. (1998) Br. J. Pharmacol. 125:1387-1392; Stadel, J.M. et al. (1997) Trends Pharmacol. Sci. 18:430-437). GPCRs are also involved in depression, schizophrenia, sleeplessness, hypertension, anxiety, stress, renal failure, and several cardiovascular disorders (Horn, F. and G. Vriend (1998) J. Mol. Med. 76:464-468).

In addition, within the past 20 years several hundred new drugs have been recognized that are directed towards activating or inhibiting GPCRs. The therapeutic targets of these drugs span a wide range of diseases and disorders, including cardiovascular, gastrointestinal, and central nervous system disorders as well as cancer, osteoporosis and endometriosis (Wilson, *supra*; Stadel, *supra*). For example, the dopamine agonist L-dopa is used to treat Parkinson's disease, while a dopamine antagonist is used to treat schizophrenia and the early stages of Huntington's disease. Agonists and antagonists of

adrenoceptors have been used for the treatment of asthma, high blood pressure, other cardiovascular disorders, and anxiety; muscarinic agonists are used in the treatment of glaucoma and tachycardia; serotonin 5HT1D antagonists are used against migraine; and histamine H1 antagonists are used against allergic and anaphylactic reactions, hay fever, itching, and motion sickness (Horn, supra).

- 5 Recent research suggests potential future therapeutic uses for GPCRs in the treatment of metabolic disorders including diabetes, obesity, and osteoporosis. For example, mutant V2 vasopressin receptors causing nephrogenic diabetes could be functionally rescued in vitro by co-expression of a C-terminal V2 receptor peptide spanning the region containing the mutations. This result suggests a possible novel strategy for disease treatment (Schöneberg, T. et al. (1996) EMBO J. 15:1283-1291).
- 10 Mutations in melanocortin-4 receptor (MC4R) are implicated in human weight regulation and obesity. As with the vasopressin V2 receptor mutants, these MC4R mutants are defective in trafficking to the plasma membrane (Ho, G. and R.G. MacKenzie (1999) J. Biol. Chem. 274:35816-35822), and thus might be treated with a similar strategy. The type 1 receptor for parathyroid hormone (PTH) is a GPCR that mediates the PTH-dependent regulation of calcium homeostasis in the bloodstream. Study
- 15 of PTH/receptor interactions may enable the development of novel PTH receptor ligands for the treatment of osteoporosis (Mannstadt, M. et al. (1999) Am. J. Physiol. 277:F665-F675).

- The chemokine receptor group of GPCRs have potential therapeutic utility in inflammation and infectious disease. (For review, see Locati, M. and P.M. Murphy (1999) Annu. Rev. Med. 50:425-440.) Chemokines are small polypeptides that act as intracellular signals in the regulation of leukocyte
- 20 trafficking, hematopoiesis, and angiogenesis. Targeted disruption of various chemokine receptors in mice indicates that these receptors play roles in pathologic inflammation and in autoimmune disorders such as multiple sclerosis. Chemokine receptors are also exploited by infectious agents, including herpesviruses and the human immunodeficiency virus (HIV-1) to facilitate infection. A truncated version of chemokine receptor CCR5, which acts as a coreceptor for infection of T-cells by HIV-1,
- 25 results in resistance to AIDS, suggesting that CCR5 antagonists could be useful in preventing the development of AIDS.

- The discovery of new G-protein coupled receptors and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, neurological, cardiovascular, gastrointestinal,
- 30 autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, G-protein coupled receptors, referred to collectively as "GCREC" and individually as "GCREC-1," "GCREC-2," "GCREC-3," "GCREC-4," "GCREC-5," "GCREC-6," "GCREC-7," "GCREC-8," "GCREC-9," "GCREC-10," "GCREC-11," "GCREC-12," "GCREC-13," "GCREC-14," "GCREC-15," "GCREC-16," "GCREC-17," "GCREC-18," "GCREC-19," "GCREC-20," and "GCREC-21." In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-21.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-21. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:22-42.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90%

sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) culturing a cell under conditions suitable for
5 expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid
10 sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21.

15 The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e)
20 an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of
25 SEQ ID NO:22-42, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide
30 in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as

an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the

activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:22-42, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted

motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"GCREC" refers to the amino acid sequences of substantially purified GCREC obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GCREC. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.

- 5 An "allelic variant" is an alternative form of the gene encoding GCREC. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.
- 10 Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

- "Altered" nucleic acid sequences encoding GCREC include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GCREC or a polypeptide with at least one functional characteristic of GCREC. Included within this definition are
- 15 polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GCREC, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GCREC. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GCREC.
- 20 Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GCREC is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity
- 25 values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

- The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic
- 30 molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

 "Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known

in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of GCREC. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by
5 directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind GCREC polypeptides can be prepared using intact polypeptides or using
10 fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize
15 the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the
20 protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as
25 phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring
30 nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic"

refers to the capability of the natural, recombinant, or synthetic GCREC, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

“Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A “composition comprising a given polynucleotide sequence” and a “composition comprising a given amino acid sequence” refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GCREC or fragments of GCREC may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

“Consensus sequence” refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

“Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
30	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
35	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val

	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
5	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
10	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

15 A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

25 A "fragment" is a unique portion of GCRC or the polynucleotide encoding GCRC which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 30 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported 35 by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:22-42 comprises a region of unique polynucleotide sequence that

specifically identifies SEQ ID NO:22-42, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:22-42 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:22-42 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:22-42 and the region of SEQ ID NO:22-42 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-21 is encoded by a fragment of SEQ ID NO:22-42. A fragment of SEQ ID NO:1-21 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-21. For example, a fragment of SEQ ID NO:1-21 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-21. The precise length of a fragment of SEQ ID NO:1-21 and the region of SEQ ID NO:1-21 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search

Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions,

explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12c sequence alignment
5 program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

10 Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

15 *Gap x drop-off: 50*

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for
20 example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to
25 describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid
30 sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity.

Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour.

Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GCREC which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of GCREC which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of GCREC. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of GCREC.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an GCREC may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by

cell type depending on the enzymatic milieu of GCREC.

"Probe" refers to nucleic acid sequences encoding GCREC, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical
5 labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

10 Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the
15 specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR
20 Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such
25 purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South
30 West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for

microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that
5 hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary
10 polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the
15 artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

20 Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs).
25 Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and
30 other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing GCREC, nucleic acids encoding GCREC, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

5 The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope
10 A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which
15 they are naturally associated.

 A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

 "Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers,
20 microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

 A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

 "Transformation" describes a process by which exogenous DNA is introduced into a recipient
25 cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells"
30 includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

 A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic

acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in
5 vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention
10 into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999)
15 set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides
20 due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given
25 species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the
30 polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human G-protein coupled receptors (GCREC), the polynucleotides encoding GCREC, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, neurological, cardiovascular, gastrointestinal,

5 autoimmune/inflammatory, and metabolic disorders, and viral infections.

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte
10 polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the
15 polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where
20 applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential
25 phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

30 As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention.

Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:22-42 or that distinguish between SEQ ID NO:22-42 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and genomic sequences in column 5 relative to their respective full length sequences.

The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 5080262H1 is the identification number of an Incyte cDNA sequence, and LNODNOT11 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., SBSA02572V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g4589483_CD) which contributed to the assembly of the full length polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, GNN.g5902227_030.edit is the identification number of a Genscan-predicted coding sequence, with g5902227 being the GenBank identification number of the sequence to which Genscan was applied. The Genscan-predicted coding sequences may have been edited prior to assembly. (See Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. (See Example V.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon-stretching" algorithm. (See Example V.) In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses GCREC variants. A preferred GCREC variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the GCREC amino acid sequence, and which contains at least one functional or

structural characteristic of GCREC.

The invention also encompasses polynucleotides which encode GCREC. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:22-42, which encodes GCREC. The polynucleotide sequences of
5 SEQ ID NO:22-42, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding GCREC. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least
10 about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GCREC. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:22-42 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:22-42.
15 Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GCREC.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GCREC, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the
20 invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GCREC, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GCREC and its variants are generally capable of
25 hybridizing to the nucleotide sequence of the naturally occurring GCREC under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GCREC or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which
30 particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GCREC and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GCREC and

GCREC derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GCREC or any fragment thereof.

5 Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:22-42 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in
10 "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or
15 combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing
20 system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

25 The nucleic acid sequences encoding GCREC may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.)
30 Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al.

(1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060).

- 5 Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a
10 GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

- When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library
15 does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

- Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the
20 emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments
25 which may be present in limited amounts in a particular sample.

- In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GCREC may be cloned in recombinant DNA molecules that direct expression of GCREC, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent
30 amino acid sequence may be produced and used to express GCREC.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GCREC-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic

oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of GCREC, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding GCREC may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, GCREC itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of GCREC, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active GCREC, the nucleotide sequences encoding GCREC or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding GCREC. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GCREC. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GCREC and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GCREC and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding GCREC. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509; Engelhard, E.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-3227; Sandig, V. et al. (1996) *Hum. Gene Ther.* 7:1937-1945; Takamatsu, N. (1987) *EMBO J.* 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659; and

Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GCREC. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding GCREC can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding GCREC into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of GCREC are needed, e.g. for the production of antibodies, vectors which direct high level expression of GCREC may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of GCREC. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of GCREC. Transcription of sequences encoding GCREC may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill,

New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GCREC may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader
5 sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses GCREC in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

10 Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of
15 GCREC in cell lines is preferred. For example, sequences encoding GCREC can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a
20 selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase
25 genes, for use in *tk*⁻ and *apr*⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980)
30 Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used.

These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GCREC is inserted within a marker gene sequence, transformed cells containing sequences encoding GCREC can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GCREC under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding GCREC and that express GCREC may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of GCREC using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GCREC is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) *Serological Methods, a Laboratory Manual*, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) *Current Protocols in Immunology*, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) *Immunochemical Protocols*, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GCREC include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding GCREC, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease

of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GCREC may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein
5 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GCREC may be designed to contain signal sequences which direct secretion of GCREC through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the
10 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities
15 (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GCREC may be ligated to a heterologous sequence resulting in translation of a
20 fusion protein in any of the aforementioned host systems. For example, a chimeric GCREC protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GCREC activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose
25 binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion
30 proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GCREC encoding sequence and the heterologous protein sequence, so that GCREC may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled GCREC may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for
5 example, ³⁵S-methionine.

GCREC of the present invention or fragments thereof may be used to screen for compounds that specifically bind to GCREC. At least one and up to a plurality of test compounds may be screened for specific binding to GCREC. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

10 In one embodiment, the compound thus identified is closely related to the natural ligand of GCREC, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which GCREC binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the
15 compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express GCREC, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing GCREC or cell membrane fractions which contain GCREC are then contacted with a test compound and binding, stimulation, or inhibition of activity of either GCREC or the
20 compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with GCREC, either in solution or affixed to a solid support, and detecting the binding of GCREC to the compound.
25 Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

GCREC of the present invention or fragments thereof may be used to screen for compounds
30 that modulate the activity of GCREC. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for GCREC activity, wherein GCREC is combined with at least one test compound, and the activity of GCREC in the presence of a test compound is compared with the activity of GCREC in the absence of the test compound. A change in the activity of GCREC in the presence of the test compound is
35 indicative of a compound that modulates the activity of GCREC. Alternatively, a test compound is

combined with an in vitro or cell-free system comprising GCREC under conditions suitable for GCREC activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of GCREC may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

- 5 In another embodiment, polynucleotides encoding GCREC or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo
10 and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D.
15 (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.
- 20 Polynucleotides encoding GCREC may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).
- 25 Polynucleotides encoding GCREC can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding GCREC is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with
30 potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress GCREC, e.g., by secreting GCREC in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists

between regions of GCREC and G-protein coupled receptors. Therefore, GCREC appears to play a role in cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections. In the treatment of disorders associated with increased GCREC expression or activity, it is desirable to decrease the expression or activity of GCREC. In the treatment of disorders associated with decreased GCREC expression or activity, it is desirable to increase the expression or activity of GCREC.

Therefore, in one embodiment, GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular

- tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse,
- 5 rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric
- 10 carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome,
- 15 colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, α_1 -antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis,
- 20 hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune
- 25 hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel
- 30 syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal,
- 35 parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes,

obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and tongavirus.

5 In another embodiment, a vector capable of expressing GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified GCREC in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a
10 disorder associated with decreased expression or activity of GCREC including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of GCREC may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those listed above.

15 In a further embodiment, an antagonist of GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC. Examples of such disorders include, but are not limited to, those cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, described above. In one aspect, an antibody which specifically binds GCREC may be used directly as an
20 antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GCREC.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC including, but not limited to, those described above.

25 In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various
30 disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of GCREC may be produced using methods which are generally known in the art. In particular, purified GCREC may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GCREC. Antibodies to GCREC may

also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

- 5 For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GCREC or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, 10 polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

- It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GCREC have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or 15 fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of GCREC amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

- Monoclonal antibodies to GCREC may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited 20 to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

- In addition, techniques developed for the production of "chimeric antibodies," such as the 25 splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GCREC-specific single 30 chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in

the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for GCREC may also be generated. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GCREC and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GCREC epitopes is generally used, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GCREC. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of GCREC-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GCREC epitopes, represents the average affinity, or avidity, of the antibodies for GCREC. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular GCREC epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the GCREC-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GCREC, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of GCREC-antibody

complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding GCREC, or any fragment
 5 or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding GCREC. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GCREC.
 10 (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g.,
 15 Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other
 20 systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding GCREC may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency
 25 (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene*
 30 *Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g.,

against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in GCREC expression or regulation causes disease, the expression of GCREC from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in GCREC are treated by constructing mammalian expression vectors encoding GCREC and introducing these vectors by mechanical means into GCREC-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of GCREC include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). GCREC may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding GCREC from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these

standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to GCREC expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding GCREC under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding GCREC to cells which have one or more genetic abnormalities with respect to the expression of GCREC. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding GCREC to target cells which have one or more genetic abnormalities with respect to the expression of GCREC. The use of herpes simplex virus (HSV)-based vectors may be

especially valuable for introducing GCREC to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 5 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this 10 patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of 15 herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding GCREC to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on 20 the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for GCREC into the alphavirus 25 genome in place of the capsid-coding region results in the production of a large number of GCREC-coding RNAs and the synthesis of high levels of GCREC in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application. 30 (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the introduction of GCREC into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases,

5 transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

10 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GCRC.

15 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of
20 candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis.

25 Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding GCRC. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

30 RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and

wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding GCRC.

- 5 Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or
10 promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased GCRC expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding GCRC may be therapeutically useful, and in the treatment of disorders associated with decreased GCRC expression or activity, a compound which specifically promotes expression of the polynucleotide encoding GCRC may be therapeutically useful.

- 15 At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound
20 based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding GCRC is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding GCRC are assayed
25 by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding GCRC. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide
30 exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a *Schizosaccharomyces pombe* gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a
35

combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

- 5 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

- 15 An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of GCREC, antibodies to GCREC, and mimetics, agonists, antagonists, or inhibitors of GCREC.

- 20 The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

- Compositions for pulmonary administration may be prepared in liquid or dry powder form.
- 25 These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising GCREC or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, GCREC or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example GCREC or fragments thereof, antibodies of GCREC, and agonists, antagonists or inhibitors of GCREC, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μ g to 100,000 μ g, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.

Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

5 In another embodiment, antibodies which specifically bind GCREC may be used for the diagnosis of disorders characterized by expression of GCREC, or in assays to monitor patients being treated with GCREC or agonists, antagonists, or inhibitors of GCREC. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for GCREC include methods which utilize the antibody and a label to detect GCREC
10 in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring GCREC, including ELISAs, RIAs, and FACS, are known
15 in the art and provide a basis for diagnosing altered or abnormal levels of GCREC expression. Normal or standard values for GCREC expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to GCREC under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of GCREC expressed in
20 subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding GCREC may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and
25 quantify gene expression in biopsied tissues in which expression of GCREC may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of GCREC, and to monitor regulation of GCREC levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GCREC or closely related molecules may be used to
30 identify nucleic acid sequences which encode GCREC. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding GCREC, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the GCREC encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:22-42 or from genomic sequences including promoters, enhancers, and introns of the GCREC gene.

- 5 Means for producing specific hybridization probes for DNAs encoding GCREC include the cloning of polynucleotide sequences encoding GCREC or GCREC derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety
- 10 of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

- Polynucleotide sequences encoding GCREC may be used for the diagnosis of disorders associated with expression of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis,
- 15 hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid,
- 20 penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating
- 25 diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis,
- 30 encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including

mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha₁-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis,

myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal
5 circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and tongavirus. The polynucleotide sequences encoding
10 GCREC may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GCREC expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding GCREC may be useful in assays that
15 detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GCREC may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control
20 sample then the presence of altered levels of nucleotide sequences encoding GCREC in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of
25 GCREC, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GCREC, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified
30 polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the

patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

5 With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

10 Additional diagnostic uses for oligonucleotides designed from the sequences encoding GCREC may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding GCREC, or a fragment of a polynucleotide complementary to the polynucleotide encoding GCREC, and will be employed under optimized conditions for identification of a specific gene or condition.

15 Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease

20 in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary

25 and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual

30 overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of GCREC include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be
5 accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray
10 can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the
15 activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, GCREC, fragments of GCREC, or antibodies specific for GCREC
20 may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by
25 quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the
30 hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the

case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and

analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are
5 visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein
10 spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

15 A proteomic profile may also be generated using antibodies specific for GCREC to quantify the levels of GCREC expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoze, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of
20 methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J.
25 Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological
30 sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the

individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding GCREC may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding GCREC on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is
5 valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may
10 also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, GCREC, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a
15 solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GCREC and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are
20 synthesized on a solid substrate. The test compounds are reacted with GCREC, or fragments thereof, and washed. Bound GCREC is then detected by methods well known in the art. Purified GCREC can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

25 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GCREC specifically compete with a test compound for binding GCREC. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GCREC.

In additional embodiments, the nucleotide sequences which encode GCREC may be used in any
30 molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are,

therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/180,093 and U.S. Ser. No. 60/182,045, are expressly incorporated by
5 reference herein.

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database
10 (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and
15 ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was
20 isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIP^T plasmid system (Life Technologies), using the
25 recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column
30 chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells

including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision
5 using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of
10 distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using
15 PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation
20 such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
25 Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997,
30 supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA

sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families.

- 5 See, for example, Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length.
- 10 Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently
- 15 analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are
- 20 generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold

- 25 parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity
- 30 between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:22-42. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative G-protein coupled receptors were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode G-protein coupled receptors, the encoded polypeptides were analyzed by querying against PFAM models for G-protein coupled receptors. Potential G-protein coupled receptors were also identified by homology to Incyte cDNA sequences that had been annotated as G-protein coupled receptors. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to

be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

10 "Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of GCREC Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:22-42 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:22-42 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

Map locations are represented by ranges, or intervals, or human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-

arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel (1995) *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding GCREC are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding GCREC. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of GCREC Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2:

94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 µl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 µl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 µl to 10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:22-42 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is

specifically described, essentially the same procedure is used with larger nucleotide fragments.

Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, *supra*), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Skena (1999), *supra*). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Skena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser

desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

5 **Tissue or Cell Sample Preparation**

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M
10 dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and
15 incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and
20 resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are
25 amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water
30 washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US
35 Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average

concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water.

- 5 Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

- Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and
10 Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for
15 about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

- Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines
20 at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

- 25 In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is
30 typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

- The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that
35 location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples

from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

5 The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and
10 measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

 A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used
15 for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

 Sequences complementary to the GCREC-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GCREC. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with
20 smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of GCREC. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GCREC-encoding transcript.

25 XII. Expression of GCREC

 Expression and purification of GCREC is achieved using bacterial or virus-based expression systems. For expression of GCREC in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid
30 promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express GCREC upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GCREC in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus

(AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GCREC by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, GCREC is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GCREC at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified GCREC obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.

XIII. Functional Assays

GCREC function is assessed by expressing the sequences encoding GCREC at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of

fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in
5 expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of GCREC on gene expression can be assessed using highly purified populations
10 of cells transfected with sequences encoding GCREC and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression
15 of mRNA encoding GCREC and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of GCREC Specific Antibodies

GCREC substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to
20 immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the GCREC amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well
25 described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the
30 oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GCREC activity by, for example, binding the peptide or GCREC to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring GCREC Using Specific Antibodies

Naturally occurring or recombinant GCREC is substantially purified by immunoaffinity

chromatography using antibodies specific for GCREC. An immunoaffinity column is constructed by covalently coupling anti-GCREC antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

5 Media containing GCREC are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of GCREC (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GCREC binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCREC is collected.

10 XVI. Identification of Molecules Which Interact with GCREC

Molecules which interact with GCREC may include agonists and antagonists, as well as molecules involved in signal transduction, such as G proteins. GCREC, or a fragment thereof, is labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) A fragment of GCREC includes, for example, a fragment comprising one or more of the
15 three extracellular loops, the extracellular N-terminal region, or the third intracellular loop. Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GCREC, washed, and any wells with labeled GCREC complex are assayed. Data obtained using different concentrations of GCREC are used to calculate values for the number, affinity, and association of GCREC with the candidate ligand molecules.

20 Alternatively, molecules interacting with GCREC are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) *Nature* 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech). GCREC may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between
25 the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Potential GCREC agonists or antagonists may be tested for activation or inhibition of GCREC receptor activity using the assays described in sections XVII and XVIII. Candidate molecules may be selected from known GPCR agonists or antagonists, peptide libraries, or combinatorial chemical
30 libraries.

Methods for detecting interactions of GCREC with intracellular signal transduction molecules such as G proteins are based on the premise that internal segments or cytoplasmic domains from an orphan G protein-coupled seven transmembrane receptor may be exchanged with the analogous domains of a known G protein-coupled seven transmembrane receptor and used to identify the G-

proteins and downstream signaling pathways activated by the orphan receptor domains (Kobilka, B.K. et al. (1988) Science 240:1310-1316). In an analogous fashion, domains of the orphan receptor may be cloned as a portion of a fusion protein and used in binding assays to demonstrate interactions with specific G proteins. Studies have shown that the third intracellular loop of G protein-coupled
5 seven transmembrane receptors is important for G protein interaction and signal transduction (Conklin, B.R. et al. (1993) Cell 73:631-641). For example, the DNA fragment corresponding to the third intracellular loop of GCREC may be amplified by the polymerase chain reaction (PCR) and subcloned into a fusion vector such as pGEX (Pharmacia Biotech). The construct is transformed into an appropriate bacterial host, induced, and the fusion protein is purified from the cell lysate by
10 glutathione-Sepharose 4B (Pharmacia Biotech) affinity chromatography.

For in vitro binding assays, cell extracts containing G proteins are prepared by extraction with 50 mM Tris, pH 7.8, 1 mM EGTA, 5 mM MgCl₂, 20 mM CHAPS, 20% glycerol, 10 µg of both aprotinin and leupeptin, and 20 µl of 50 mM phenylmethylsulfonyl fluoride. The lysate is incubated on ice for 45 min with constant stirring, centrifuged at 23,000 g for 15 min at 4°C, and the
15 supernatant is collected. 750 µg of cell extract is incubated with glutathione S-transferase (GST) fusion protein beads for 2 h at 4°C. The GST beads are washed five times with phosphate-buffered saline. Bound G subunits are detected by [³²P]ADP-ribosylation with pertussis or cholera toxins. The reactions are terminated by the addition of SDS sample buffer (4.6% (w/v) SDS, 10% (v/v) β-mercaptoethanol, 20% (w/v) glycerol, 95.2 mM Tris-HCl, pH 6.8, 0.01% (w/v) bromophenol blue).
20 The [³²P]ADP-labeled proteins are separated on 10% SDS-PAGE gels, and autoradiographed. The separated proteins in these gels are transferred to nitrocellulose paper, blocked with blotto (5% nonfat dried milk, 50 mM Tris-HCl (pH 8.0), 2 mM CaCl₂, 80 mM NaCl, 0.02% NaN₃, and 0.2% Nonidet P-40) for 1 hour at room temperature, followed by incubation for 1.5 hours with Gα subtype selective antibodies (1:500; Calbiochem-Novabiochem). After three washes, blots are incubated with
25 horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin (1:2000, Cappel, Westchester PA) and visualized by the chemiluminescence-based ECL method (Amersham Corp.).

XVII. Demonstration of GCREC Activity

An assay for GCREC activity measures the expression of GCREC on the cell surface. cDNA encoding GCREC is transfected into an appropriate mammalian cell line. Cell surface proteins are
30 labeled with biotin as described (de la Fuente, M.A. et al. (1997) Blood 90:2398-2405). Immunoprecipitations are performed using GCREC-specific antibodies, and immunoprecipitated samples are analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of GCREC expressed on the cell surface.

35 In the alternative, an assay for GCREC activity is based on a prototypical assay for

ligand/receptor-mediated modulation of cell proliferation. This assay measures the rate of DNA synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding GCREC is added to quiescent 3T3 cultured cells using transfection methods well known in the art. The transiently transfected cells are then incubated in the presence of [3 H]thymidine, a radioactive DNA precursor molecule. Varying amounts of GCREC ligand are then added to the cultured cells. Incorporation of [3 H]thymidine into acid-precipitable DNA is measured over an appropriate time interval using a radioisotope counter, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold GCREC ligand concentration range is indicative of receptor activity. One unit of activity per milliliter is defined as the concentration of GCREC producing a 50% response level, where 100% represents maximal incorporation of [3 H]thymidine into acid-precipitable DNA (McKay, I. and I. Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York NY, p. 73.)

In a further alternative, the assay for GCREC activity is based upon the ability of GPCR family proteins to modulate G protein-activated second messenger signal transduction pathways (e.g., cAMP; Gaudin, P. et al. (1998) J. Biol. Chem. 273:4990-4996). A plasmid encoding full length GCREC is transfected into a mammalian cell line (e.g., Chinese hamster ovary (CHO) or human embryonic kidney (HEK-293) cell lines) using methods well-known in the art. Transfected cells are grown in 12-well trays in culture medium for 48 hours, then the culture medium is discarded, and the attached cells are gently washed with PBS. The cells are then incubated in culture medium with or without ligand for 30 minutes, then the medium is removed and cells lysed by treatment with 1 M perchloric acid. The cAMP levels in the lysate are measured by radioimmunoassay using methods well-known in the art. Changes in the levels of cAMP in the lysate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

To measure changes in inositol phosphate levels, the cells are grown in 24-well plates containing 1×10^5 cells/well and incubated with inositol-free media and [3 H]myoinositol, 2 μ Ci/well, for 48 hr. The culture medium is removed, and the cells washed with buffer containing 10 mM LiCl followed by addition of ligand. The reaction is stopped by addition of perchloric acid. Inositol phosphates are extracted and separated on Dowex AG1-X8 (Bio-Rad) anion exchange resin, and the total labeled inositol phosphates counted by liquid scintillation. Changes in the levels of labeled inositol phosphate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

XVIII. Identification of GCREC Ligands

GCREC is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK

(Human Embryonic Kidney) 293 which have a good history of GPCR expression and which contain a wide range of G-proteins allowing for functional coupling of the expressed GCREC to downstream effectors. The transformed cells are assayed for activation of the expressed receptors in the presence of candidate ligands. Activity is measured by changes in intracellular second messengers, such as cyclic AMP or Ca^{2+} . These may be measured directly using standard methods well known in the art, or by the use of reporter gene assays in which a luminescent protein (e.g. firefly luciferase or green fluorescent protein) is under the transcriptional control of a promoter responsive to the stimulation of protein kinase C by the activated receptor (Milligan, G. et al. (1996) Trends Pharmacol. Sci. 17:235-237). Assay technologies are available for both of these second messenger systems to allow high throughput readout in multi-well plate format, such as the adenylyl cyclase activation FlashPlate Assay (NEN Life Sciences Products), or fluorescent Ca^{2+} indicators such as Fluo-4 AM (Molecular Probes) in combination with the FLIPR fluorimetric plate reading system (Molecular Devices). In cases where the physiologically relevant second messenger pathway is not known, GCREC may be coexpressed with the G-proteins $\text{G}_{\alpha 15/16}$ which have been demonstrated to couple to a wide range of G-proteins (Offermanns, S. and M.I. Simon (1995) J. Biol. Chem. 270:15175-15180), in order to funnel the signal transduction of the GCREC through a pathway involving phospholipase C and Ca^{2+} mobilization. Alternatively, GCREC may be expressed in engineered yeast systems which lack endogenous GPCRs, thus providing the advantage of a null background for GCREC activation screening. These yeast systems substitute a human GPCR and G_{α} protein for the corresponding components of the endogenous yeast pheromone receptor pathway. Downstream signaling pathways are also modified so that the normal yeast response to the signal is converted to positive growth on selective media or to reporter gene expression (Broach, J.R. and J. Thorner (1996) Nature 384 (supp.):14-16). The receptors are screened against putative ligands including known GPCR ligands and other naturally occurring bioactive molecules. Biological extracts from tissues, biological fluids and cell supernatants are also screened.

25

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

30

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
7472033	1	7472033CD1	22	7472033CB1
7472034	2	7472034CD1	23	7472034CB1
7472035	3	7472035CD1	24	7472035CB1
7472036	4	7472036CD1	25	7472036CB1
7472037	5	7472037CD1	26	7472037CB1
7472039	6	7472039CD1	27	7472039CB1
7472040	7	7472040CD1	28	7472040CB1
4250893	8	4250893CD1	29	4250893CB1
6726656	9	6726656CD1	30	6726656CB1
7472062	10	7472062CD1	31	7472062CB1
7472067	11	7472067CD1	32	7472067CB1
7472072	12	7472072CD1	33	7472072CB1
7472074	13	7472074CD1	34	7472074CB1
7472077	14	7472077CD1	35	7472077CB1
7472082	15	7472082CD1	36	7472082CB1
7472128	16	7472128CD1	37	7472128CB1
7472134	17	7472134CD1	38	7472134CB1
7472136	18	7472136CD1	39	7472136CB1
7472142	19	7472142CD1	40	7472142CB1
7472171	20	7472171CD1	41	7472171CB1
7472172	21	7472172CD1	42	7472172CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability Score	GenBank Homolog
1	7472033CD1	g4062997	4.3e-38	Neuropeptide Y receptor type 4 [Sus scrofa]
2	7472034CD1	g6532001	3.6e-89	Odorant receptor S19 [Mus musculus]
3	7472035CD1	g4680260	2.5e-72	Odorant receptor S18 [Mus musculus]
4	7472036CD1	g4680260	2.9e-87	Odorant receptor S18 [Mus musculus]
5	7472037CD1	g32093	2.5e-81	Olfactory receptor HGMP07J [Homo sapiens]
6	7472039CD1	g3983374	9.3e-75	Olfactory receptor C6 [Mus musculus]
7	7472040CD1	g7707801	1.0e-177	G protein-coupled receptor C5L2 [Homo sapiens]
8	4250893CD1	g3341996	5.0e-65	Angiotensin/vasopressin receptor AII/AVP [Homo sapiens] (Mao, M. et al. (1998) Proc. Natl. Acad. Sci. USA 95(14):8175-8180)
9	6726656CD1	g3983408	7.4e-82	Olfactory receptor H7 [Mus musculus] (Krautwurst, D. et al. (1998) Cell 95(7):917-926)
10	7472062CD1	g3746443	7.6e-80	Olfactory receptor OR93Ch [Pan troglodytes] (Rouquier, S. et al. (1998) Hum. Mol. Genet. 7(9):1337-1345)
11	7472067CD1	g2358267	6.3e-23	Galanin receptor [Mus musculus] (Jacoby, A.S. et al. (1997) Genomics 45(3):496-508)
12	7472072CD1	g1336043	3.4e-68	HsOLF3 [Homo sapiens]
13	7472074CD1	g10732802	1.0e-47	Vomeranase receptor 1 [Homo sapiens]
14	7472077CD1	g8118040	1.0e-168	Orphan G-protein coupled receptor [Homo sapiens]
15	7472082CD1	g2317704	2.2e-114	Olfactory receptor [Rattus norvegicus] (McClintock, T.S. et al. (1997) Brain Res. Mol. Brain Res. 2:59-68)
16	7472128CD1	g1246534	3.5e-82	Olfactory receptor 4 [Gallus gallus] (Leibovici, M. et al. (1996) Dev. Biol. 175(1):118-131)
17	7472134CD1	g4680254	1.4e-78	Odorant receptor S1 [Mus musculus] (Malnic, B. et al. (1999) Cell 96(5):713-723)
18	7472136CD1	g206810	1.3e-43	G-protein coupled receptor [Rattus norvegicus] (Ross, P.C. et al. (1990) Proc. Natl. Acad. Sci. USA 87:3052-3056)
19	7472142CD1	g5869918	1.0e-93	Olfactory receptor [Mus musculus] (Strotmann, J. et al. (1999) Gene 236(2):281-291)
20	7472171CD1	g5869925	1.6e-134	Olfactory receptor [Mus musculus] (Strotmann, J. et al. (1999) Gene 236(2):281-291)
21	7472172CD1	g3983374	3.9e-76	Olfactory receptor C6 [Mus musculus] (Krautwurst, D. et al. (1998) Cell 95(7):917-926)

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	7472033CD1	470	S131 T153 S24 S73 Y82	N2 N46 N51 N56	G-protein coupled receptor motif: V184-I200 Transmembrane domains: P80-Y105, L145-Y164, V214-Y234, Y271-Y291 7 transmembrane receptor (rhodopsin family) signature: L140-Y379 G-protein coupled receptor signatures: Y164-P203, Y280-Y291, R316-F342, S371-R387 G-protein coupled receptor signature: A175-A224 Neuropeptide Y receptor signatures: T153-G165, Q178-A193, R314-I326, M366-N375, L377-I390 Rhodopsin-like GPCR superfamily signatures: M84-S108, Q178-I200, G212-V233, F269-A290, S272-Y295, T321-Y345, Y361-R387 Probable G protein-coupled receptor signatures: I174-A191, G380-L393 T22D1.12 protein (similar to G-protein coupled receptors): PD061410; Y271-A415 G-protein coupled receptor: PD000009; L140-Y234	MOTIFS HMMER HMMER-PFAM BLIMPS-BLOCKS PROFILESKAN BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1					G-protein coupled receptor DM00013 P49683 54-350: L140-L394 DM00013 P50391 35-337: S141-L394 DM00013 P49146 44-341: M84-K388 DM00013 P25929 34-335: S141-Q391	BLAST-DOMO
2	7472034CD1	326	T276 T323 S123 T323	N57	G-protein coupled receptor motif: M125-I141 Transmembrane domains: W61-D67, M161-C184, T208-G230 7 transmembrane receptor (rhodopsin family) signature: G56-Y307 G-protein coupled receptor signatures: H105-P144, E247-S273, F266-H277, P299-R315 Olfactory receptor signatures: M74-K95, A192-E206, F253-V268 Rhodopsin-like GPCR superfamily signatures: W41-F62, W41-W65, M74-K95, I119-I141, G214-L237, A252-T276, V289-R315 Olfactory receptor PD000921: L181-I260 Putative G-protein coupled receptor RA1c PDI70483: I260-F322 G-protein coupled receptor: DM00013 P23269 15-304: I32-V321 DM00013 P30955 18-305: L49-V321 DM00013 S29708 18-306: Q39-V321 DM00013 P23274 18-306: E37-V321	MOTIFS HMMER HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
3	7472035CD1	315	T49 T103 S172 S48 T144 S224		G-protein coupled receptor motif: V105-I121 Signal peptide: M1-A28 Transmembrane domain: Y30-S48 7 transmembrane receptor (rhodopsin family) signature: G36-Y288 G-protein coupled receptor signatures: S85-P124, T227-S253, P280-R296 G-protein coupled receptor signature: F97-R146 Olfactory receptor signatures: M54-K75, S172-D186, L233-L248 Angiotensin II receptor signature: I209-V220 EDG1 orphan receptor signature: A43-F57 Olfactory receptor PD000921: L161-V240 G-protein coupled receptor: DM00013 P23274 18-306: I12-I299 DM00013 G45774 18-309: P13-E297 DM00013 S29708 18-306: H19-I299 DM00013 P23269 15-304: Q16-I299 G-protein coupled receptor motif: M112-I128 Transmembrane domains: I27-L42, I199-L218 7 transmembrane receptor (rhodopsin family) signature: G43-Y294	MOTIFS HMMER HMMER HMMER-PFAM BLIMPS-BLOCKS PROFILES SCAN BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO MOTIFS HMMER HMMER-PFAM
4	7472036CD1	314	S110	N5 N44		

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
4					<p>G-protein coupled receptor signatures: R92-P131, E234-S260, P286-R302</p> <p>G-protein coupled receptor signature: F104-A152</p> <p>Olfactory receptor signatures: M61-K82, C179-D193, F240-T255, L278-V289</p> <p>Melanocortin receptor signature: A53-L65</p> <p>Rhodopsin-like GPCR superfamily signatures: W28-Q52, M61-K82, L106-I128, I143-L164, G201-L224, A203-V227, I276-R302</p> <p>Olfactory receptor PD000921: Y170-I247</p> <p>Putative G-protein coupled receptor RA1c PD170483: I247-F309</p> <p>G-protein coupled receptor: DM00013 P23275 17-306: H24-I305 DM00013 G45774 18-309: P20-I305 DM00013 S29708 18-306: E23-V308 DM00013 P23269 15-304: E23-V308</p> <p>Transmembrane domains: P33-G49, V148-I171, L205-I229</p> <p>7 transmembrane receptor (rhodopsin family) signature: G49-Y298</p>	<p>BLIMPS-BLOCKS</p> <p>PROFILESCAN</p> <p>BLIMPS-PRINTS</p> <p>BLIMPS-PRINTS</p> <p>BLIMPS-PRINTS</p> <p>BLAST-PRODOM</p> <p>BLAST-PRODOM</p> <p>BLAST-DOMO</p> <p>HMMER</p> <p>HMMER-PFAM</p>
5	7472037CD1	321	S75 S196 S201 S240 T299	N12 N50		

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
5					G-protein coupled receptor signatures: Q98-P137, F208-F219, R243-R269, T290-R306 G-protein coupled receptor signature: F110-S159 Olfactory receptor signatures: M67-N88, F185-E199, F246-G261, V282-L293, T299-L313 Melanocortin receptor signature: V59-L71, I134-R145 Olfactory receptor PD000921: F176-L253 Olfactory receptor PD149621: T254-R315 G-protein coupled receptor: DM00013 P30954 29-316: S26-L309 DM00013 P23270 18-311: L31-L313 DM00013 P30955 18-305: P29-K311 DM00013 S29709 11-299: P29-L313	BLIMPS-BLOCKS PROFILESCAN BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM BLAST-DOMO
6	7472039CDL	331	S69 S24 T195 S235 S326	N6 N40 N67	G-protein coupled receptor motif: S112-I128 Signal peptide: M1-A53 Transmembrane domains: M61-L84, A98-M120, S207-L229, F241-V263 7 transmembrane receptor (rhodopsin family) signature: G43-Y293 G-protein coupled receptor signatures: H92-P131, Q238-R264, T285-K301	MOTIFS SPSCAN HMME HMME-PFAM BLIMPS-BLOCKS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
6					G-protein coupled receptor signature: Y104-A149 Olfactory receptor signatures: M61-K82, F180-N194, F241-G256, V277-L288, A294-F308 Melanocortin receptor signature: A53-L65, I128-S139 Olfactory receptor PD000921: L168-I249 Olfactory receptor PD149621: V250-K310 G-protein coupled receptor: DM00013 P23267 20-309: P20-K305 DM00013 P23270 18-311: R26-K305 DM00013 P23274 18-306: F30-L304 DM00013 P30955 18-305: F30-K305	PROFILES-SCAN BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM BLAST-PRODOM
7	7472040CD1	337	S17 S323 S326 S194 T327 S333	N3	7 transmembrane receptor (rhodopsin family) signature: G52-D131, V153-F291 G-protein coupled receptor signatures: W100-P139, F209-H220, W226-L252, H283-L299 C5A-anaphylatoxin receptor signatures: V59-W72, C83-P93, L110-S121 P111-L123 Rhodopsin-like GPCR superfamily signatures: A37-G61, G69-L90, I114-A136, G150-I171, T201-L224, C231-V255, E273-L299	HMME-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLIMPS-PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
7					Prostanoid EP1 receptor signature: W58-L73 G-protein coupled receptor: PD000009: W72-Y172 G-protein coupled receptor: DM00013 P30992 32-317: L39-L292 DM00013 P21730 31-315: V36-L303 DM00013 P30993 27-313: P33-P304 DM00013 A46525 31-317: P33-P304	BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO
8	4250893CD1	1473	S990 S37 S49 S99 S162 S258 S299 S368 S379 S400 S485 S509 S587 T747 T850 T866 T868 S923 T962 T993 S1047 S1064 T1075 S1313 S1371 T1394 S132 S144 S227 T457 S484 T543 T670 T831 T841 S893 S985 S1009 S1017 S1107 S1258 S1464 Y1311 Y1445	N727 N864 N1005	Transmembrane domain: G1216-L1237 Leucine Rich Repeats: N809-R833; L838-R862; T866-R890; K895-P922; S923-R947 RECEPTOR ANGIOTENSIN/VASOPRESSIN AII/AVP VASOPRESSIN PD156095: M534-V704 ATP/GTP binding site (P-loop): G334-S341	HMMER HMMER-PFAM BLAST-PRODOM MOTIFS
9	6726656CD1	328	S17 T309	N23	Transmembrane domains: V43-I63; Y211-M231 7 transmembrane receptors (rhodopsin family) domain: G59-Y308 G-protein coupled receptors signature: S108-P147; S300-K316	HMMER HMMER-PFAM BLIMPS-BLOCKS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9					G-protein coupled receptors signature: Y120-V166 Olfactory receptor signature: M77-K98; F195-S209; F256-T271; A292-L303; T309-F323 RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L184-L263 G-PROTEIN COUPLED RECEPTORS DM00013 P23266 17-306: S36-L322 G-protein coupled receptors motif: S128-I144	PROFILES SCAN BLIMPS-PRINTS BLAST-PRODROM BLAST-DOMO MOTIFS
10	7472062CD1	384	T298 S34 S36 T69 T256 S10 T146 T205 T231 S258 T338 T359 Y378	N49 N73 N133 N223	Transmembrane domains: F96-L116; V268-I291; G310-I328 7 transmembrane receptor (rhodopsin family) domain: G109-Y358 G-protein coupled receptors signature: K158-P197; I350-K366 G-protein coupled receptors signature: F170-G215 Olfactory receptor signature: M127-K148; F245-E259; L306-I321; A342-L353; T359-V373	HMNER HMNER-PFAM BLIMPS-BLOCKS PROFILES SCAN BLIMPS-PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
10					OLFACTORY RECEPTOR PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD149621; I316-V373 G-PROTEIN COUPLED RECEPTORS DM00013 S51356 18-307; L85-A368 G-protein coupled receptors motif: V178-V194	BLAST-PRODOR BLAST-DOMO MOTIFS
11	7472067CD1	419	T234 S81 S102 T331 S358 S398 T177 T326 S370 T375	N10 N15 N79 N151	Transmembrane domain: A41-L61 7 transmembrane receptor (rhodopsin family) domain: G53-A133; W155-F306 G-protein coupled receptors signature: W104-P143; I243-A269; I298-R314 Rhodopsin-like GPCR superfamily signature: I38-L62; I73-I94; T153-F174; V248-W272; I288-R314 G-PROTEIN COUPLED RECEPTORS DM00013 P47211 27-319; V49-K322	HMMER HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-DOMO
12	7472072CD1	314	S67 S188 S227 S291	N5 N155	Transmembrane domains: L30-F47; I101-M118; M197-I214 7 transmembrane receptor (rhodopsin family) domain: G41-Y290 G-protein coupled receptors signature: G90-P129; L207-Y218; T282-W298	HMMER HMMER-PFAM BLIMPS-BLOCKS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
12					G-protein coupled receptors signature: F102-S147 Rhodopsin-like GPCR superfamily signature: L26-R50; M59-K80; L104-V126; L199-L222; A237-V261; N272-W298 Olfactory receptor signature: M59-K80; F177-D191; V238-G253; V274-L285; S291-L305 RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: Y168-I245 G-PROTEIN COUPLED RECEPTORS DM00013 P23275 17-306; L26-L305	PROFILES SCAN BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODROM BLAST-DOMO
13	7472074CD1	254	T159 S185 S110 S111 T150 T178 S222	N154 N157	G-protein coupled receptors motif: A110-V126 Signal peptide: M1-G61 Transmembrane domain: V127-F145; M182-S199; I235-V254 5-hydroxytryptamine 2A receptor signature: H48-A68 G-protein coupled receptors signature: Y73-R112; S226-F252 PHEROMONE RECEPTOR VN1 VN2 VN3 VN7 VN5 VN4 VN6 PD009900: R38-Y246	MOTIFS SPSCAN MOTIFS BLIMPS-PRINTS BLIMPS-BLOCKS BLAST-PRODROM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
14	7472077CD1	362	S8 S268		<p>Transmembrane domains: S28-M48; F66-N85; V91-A109; C164-M181; L205-L224; W251-N278</p> <p>7 transmembrane receptor (metabotropic glutamate family) domain: W22-Q271 (Score: -137.1; E-value: 0.35)</p> <p>B1 bradykinin receptor signature: T37-Q56</p> <p>PROTEIN BRIDE OF SEVENLESS PRECURSOR TRANSMEMBRANE GLYCOPROTEIN VISION SIGNAL PD151485; V91-P260</p>	<p>HMMEER</p> <p>HMMEER-PFAM</p> <p>BLIMPS-PRINTS BLAST-PRODROM</p>
15	7472082CD1	370	S334 S42 S68 S127 S153 S326 T138 T147 S351	N65	<p>Transmembrane domains: F88-L108; W203-L228; L260-A283</p> <p>7 transmembrane receptor (rhodopsin family) domain: G101-Y350</p> <p>G-protein coupled receptors signature: N150-P189; V342-K358</p> <p>Olfactory receptor signature: M119-K140; Y237-S251; F298-G313; S334-L345; S351-L365</p> <p>RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921; L226-L306</p> <p>G-PROTEIN COUPLED RECEPTORS DM00013 S51356 18-307; L77-V361</p>	<p>HMMEER</p> <p>HMMEER-PFAM</p> <p>BLIMPS-BLOCKS</p> <p>BLIMPS-PRINTS</p> <p>BLAST-PRODROM</p> <p>BLAST-DOMO</p>

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
16	7472128CD1	319	T2 S74 T85 S95 T201 S298	N274	Transmembrane domain: V204-C226 7 transmembrane receptor (rhodopsin family) domain: G48-Y297 G-protein coupled receptors signature: K97-P136; T214-Y225; I289-K305 G-protein coupled receptors signature: F110-A157 Olfactory receptor signature: M66-K87; Y184-N198 L245-G260; V281-L292; S298-L312 RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L173-L253 G-PROTEIN COUPLED RECEPTORS DM00013 S51356 18-307: P28-R310 G-protein coupled receptors motif: A117-I133 Signal peptide: M1-G41 Transmembrane domains: L29-V48; I207-L226; I238-L262 7 transmembrane receptor (rhodopsin family) domain: G41-Y290 G-protein coupled receptors signature: K90-P129; T282-K298	HMME HMME-PFAM BLIMPS-BLOCKS PROFILESCAN BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO MOTIFS SPSCAN HMME HMME-PFAM BLIMPS-BLOCKS
17	7472134CD1	312	S67 S87 S204 S291	N5		

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
17					G-protein coupled receptors signature: Y102-I146 Rhodopsin-like GPCR superfamily signature: Y26-C50; M59-K80; F104-I126; D199-I222; Q272-K298 Olfactory receptor signature: M59-K80; V177-D191; I238-G253; L274-L285; S291-L305 RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L166-H244 G-PROTEIN COUPLED RECEPTORS DM00013 P23267 20-309: F17-K306 G-protein coupled receptors motif: T110-I126	PROFILES SCAN BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO MOTIFS
18	7472136CD1	321	S209 T94 T121 S281 S284	N2 N6 N16 N92	Transmembrane domain: Y109-F129; V229-Y245 7 transmembrane receptor (rhodopsin family) domain: G44-S78; L104-Y276 G-protein coupled receptors signature: V91-P130; R214-Y240; S268-S284 G-protein coupled receptors signature: L104-L149	HMMER HMMER-PFAM BLIMPS-BLOCKS PROFILES SCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
18					Rhodopsin-like GPCR superfamily signature: V29-G53; F61-T82; M105-V127; L219-V243; F258-S284	BLIMPS-PRINTS
					GPROTEIN COUPLED RECEPTOR TRANSMEMBRANE GLYCOPROTEIN MAS PROTOONCOGENE G PROTEINCOUPLED PROBABLE PD013244: C175-E305	BLAST-PRODROM
					G-PROTEIN COUPLED RECEPTORS DM00013 P23749 38-307; V29-L287	BLAST-DOMO
19	7472142CD1	316	T49 S67 T228 S88 S290	N5 N42 N65	Transmembrane domains: F28-I48; Y102-D121; L199-I227 7 transmembrane receptor (rhodopsin family) domain: G41-Y289	HMNER
					G-protein coupled receptors signature: K90-P129; T281-K297	BLIMPS-BLOCKS
					G-protein coupled receptors signature: Y102-V147	PROFILESKAN
					Visual pigments (opsins) retinal binding site: S262-H315	PROFILESKAN
					Rhodopsin-like GPCR superfamily signature: V26-I50; M59-T80; S104-I126; M198-L221; A236-K260; K271-K297	BLIMPS-PRINTS
					Olfactory receptor signature: M59-T80; F176-S190; F237-G252; I273-L284; S290-L304	BLIMPS-PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
19					RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L166-L244 G-PROTEIN COUPLED RECEPTORS DM00013 P23275 17-306: S18-G305 G-protein coupled receptors motif: T110-I126	BLAST- PRODOM BLAST-DOMO MOTIFS
20	7472171CD1	325	S49 S67 T118 S156 S193 S87 S88 S137 S163 T178 S291	N5 N65 N191	Transmembrane domain: L143-S163; S203-V228 7 transmembrane receptor (rhodopsin family) domain: G41-Y290 G-protein coupled receptors signature: K90-P129; T282-K298 G-protein coupled receptors signature: L103-A147 Olfactory receptor signature: V59-L80; F177-N191; F238-G253; F274-L285; S291-W305 RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L166-L245 G-PROTEIN COUPLED RECEPTORS DM00013 A57069 15-304: F17-G306 G-protein coupled receptors motif: T110-I126	HMME HMME-PFAM BLIMPS- BLOCKS PROFILES SCAN BLIMPS- PRINTS BLAST- PRODOM BLAST-DOMO MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
21	7472172CD1	313	T6 S65 S263 T76 S288	N3 N40 N63 N262	Signal peptide: M1-T36 Transmembrane domains: I10-T32; M96-M116; L191-L208 7 transmembrane receptor (rhodopsin family) domain: G39-Y287 G-protein coupled receptors signature: K88-P127; T279-Q295 G-protein coupled receptors signature: Y100-L144 Rhodopsin-like GPCR superfamily signature: S24-W48; M57-K78; Y102-I124; A138-I159; N196-I219; K269-Q295 Olfactory receptor signature: M57-K78; F174-N188; F235-G250; A271-L282; S288-V302 RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L164-I242 G-PROTEIN COUPLED RECEPTORS DM00013 P23267 20-309: F15-V302 G-protein coupled receptors motif: V108-I124	SPSCAN HMMER HMMER-PFAM BLOCKS-BLIMPS PROFILESCAN BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOR BLAST-DOMO MOTIFS

Table 4

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
22	7472033CB1	1413	1-1413	GNN.g5902227_030.edit	1	1413
23	7472034CB1	1076	212-1076	GNN.g6087993_008.edit	1	1076
24	7472035CB1	948	1-87, 908-948, 377-798	GNN.g6088009_006	1	948
25	7472036CB1	945	1-36	GNN.g6088009_016	1	945
26	7472037CB1	966	1-46, 931-966	GNN.g6094563_010	1	966
27	7472039CB1	996	1-94, 585-996, 454-524	GNN.g6094604_016	1	996
28	7472040CB1	1014	1-843	GNN.g6165152_010	1	1014
29	4250893CB1	5122	3275-3357, 1-1445, 4869-5122, 2954-3232, 4873-4944, 4411-4479, 1740-2862, 3840-4064	SBSA02572V1 5080262H1 (LNODNOT11) 4882636F6 (LUNLTWT01) 639691X12F1 (BRSTNOT03) 2654889F6 (THYMNOT04) g4589483_CD 2831336F6 (TLYMNOT03) SAFB00488F1 1559811H1 (SPLNNOT04) 3345781H1 (SPLNNOT09) 4220888H1 (PANCNOT07) 5090301F6 (UTRSTMR01) 504356R6 (TMLR3DT02) SBSA00168V1 SAFC01343F1 4882636T6 (LUNLTWT01)	4180 2345 508 2904 2372 339 1 3464 3448 1626 3883 1659 4586 4155 3022 621	4818 2606 909 3418 2912 4294 513 4111 3642 1884 4171 2322 5122 4681 3565 1150

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte polynucleotide ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
30	6726656CB1	1241	1-311	GNN.g6524208_008	312	1241
31	7472062CB1	1155	1-211, 649-921, 1104-1155	6726656H1 (COLITUT02) GNN.g6009916_000010_002	1	580
32	7472067CB1	1260	1-1260	GNN.g6013566_000014_004	1	1260
33	7472072CB1	945	920-945	GNN.g6165017_000177_002	1	945
34	7472074CB1	765	538-765	GNN.g6165058_000059_002	1	765
35	7472077CB1	1089	897-944	GNN.g5815499_006	1	1089
36	7472082CB1	1334	1-181	GNN.g6521401_012 g5754986	1	1113
37	7472128CB1	960	1-22, 477-642, 940-960	GNN.g6451812_008.edit	883	1334
38	7472134CB1	939	1-223, 756-804, 587-627	GNN.g6479069_014	1	939
39	7472136CB1	968	1-968	GNN.g6498052_008.edit	1	968
40	7472142CB1	1000	1-82, 975-1000, 563-684	GNN.g6524207_010.edit	1	1000
41	7472171CB1	1008	1-33, 931-1008	GNN.g6562243_020.edit	1	1008
42	7472172CB1	972	1-29, 605-972	GNN.g6525268_002.edit	1	972

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID	Representative Library
29	4250893CB1	SYNORAT05
30	6726656CB1	COLITUT02

Table 6

Library	Vector	Library Description
COLITUT02	pINCY	Library was constructed using RNA isolated from colon tumor tissue of the ileocecal valve removed from a 29-year-old female. Pathology indicated malignant lymphoma, small cell, non-cleaved (Burkitt's lymphoma, B-cell phenotype), forming a polypoid mass in the region of the ileocecal valve, associated with intussusception and obstruction clinically. The liver and multiple (3 of 12) ileocecal region lymph nodes were also involved by lymphoma.
SYNORAT05	PSPORT1	Library was constructed using RNA isolated from the knee synovial tissue of a 62-year-old female with rheumatoid arthritis.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLOCKS IMPROVED Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less Signal peptide hits: Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- 5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21,
 b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21,
 c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and
10 d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21.

2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-21.

15

3. An isolated polynucleotide encoding a polypeptide of claim 1.

4. An isolated polynucleotide encoding a polypeptide of claim 2.

20

5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:22-42.

6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

25

7. A cell transformed with a recombinant polynucleotide of claim 6.

8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

30

9. A method for producing a polypeptide of claim 1, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

35

b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.

11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- 5 a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42,
 b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42,
 c) a polynucleotide sequence complementary to a),
 d) a polynucleotide sequence complementary to b), and
10 e) an RNA equivalent of a)-d).

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization
20 complex is formed between said probe and said target polynucleotide or fragments thereof, and
 b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.
25

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
30 b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
35

17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-21.

18. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

21. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. A method for treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a

compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- 5 a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in
- 10 the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method

15 comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of
- 20 the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at
- 25 least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
- c) quantifying the amount of hybridization complex; and
- 30 d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

<110> INCYTE GENOMICS, INC.
 BAUGHN, Mariah R.
 AU-YOUNG, Janice
 YUE, Henry

<120> G-PROTEIN COUPLED RECEPTORS

<130> PI-0032 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/180,093; 60/182,045

<151> 2000-02-02; 2000-02-11

<160> 42

<170> PERL Program

<210> 1

<211> 470

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472033CD1

<220>

<221> unsure

<222> 59, 128, 309

<223> unknown or other

<400> 1

Met	Asn	Gln	Thr	Glu	Pro	Ala	Gln	Leu	Ala	Asp	Gly	Glu	His	Leu
1				5					10					15
Ser	Gly	Tyr	Ala	Ser	Ser	Ser	Asn	Ser	Val	Arg	Tyr	Leu	Asp	Asp
				20					25					30
Arg	His	Pro	Leu	Asp	Tyr	Leu	Asp	Leu	Gly	Thr	Val	His	Ala	Leu
				35					40					45
Asn	Thr	Thr	Ala	Ile	Asn	Thr	Ser	Asp	Leu	Asn	Glu	Thr	Xaa	Ser
				50					55					60
Arg	Pro	Leu	Asp	Pro	Val	Leu	Ile	Asp	Arg	Phe	Leu	Ser	Asn	Arg
				65					70					75
Ala	Val	Asp	Ser	Pro	Trp	Tyr	His	Met	Leu	Ile	Ser	Met	Tyr	Gly
				80					85					90
Val	Leu	Ile	Val	Phe	Gly	Ala	Leu	Gly	Asn	Thr	Leu	Gly	Cys	Tyr
				95					100					105
Ser	Pro	Ser	Ser	Gly	Ser	Pro	Ser	Cys	Ala	Leu	Leu	Ala	Ile	Trp
				110					115					120
Phe	Ile	Leu	Asn	Leu	Ala	Ile	Xaa	Gly	Gln	Ser	Lys	Cys	Glu	Ser
				125					130					135
His	Pro	Ser	Gly	Leu	Ser	Asp	Leu	Leu	Leu	Cys	Leu	Val	Thr	Met
				140					145					150
Pro	Leu	Thr	Leu	Met	Glu	Ile	Leu	Ser	Lys	Tyr	Trp	Pro	Tyr	Gly
				155					160					165
Ser	Cys	Ser	Ile	Leu	Cys	Lys	Thr	Ile	Ala	Met	Leu	Gln	Ala	Leu
				170					175					180
Cys	Ile	Phe	Val	Ser	Thr	Ile	Ser	Ile	Thr	Ala	Ile	Ala	Phe	Asp
				185					190					195
Arg	Tyr	Gln	Val	Ile	Val	Tyr	Pro	Thr	Arg	Asp	Ser	Leu	Gln	Phe
				200					205					210
Val	Gly	Ala	Val	Thr	Ile	Leu	Ala	Gly	Ile	Trp	Ala	Leu	Ala	Leu
				215					220					225
Leu	Leu	Ala	Ser	Pro	Leu	Phe	Val	Tyr	Lys	Glu	Leu	Ile	Asn	Thr
				230					235					240
Asp	Thr	Pro	Ala	Leu	Leu	Gln	Gln	Ile	Gly	Leu	Gln	Asp	Thr	Ile

Pro	Tyr	Cys	Ile	245	Glu	Asp	Trp	Pro	Ser	250	Arg	Asn	Gly	Arg	Phe	255	Tyr
				260	Ser	Leu	Cys	Val	Gln	265	Tyr	Leu	Val	Pro	Ile	270	Leu
Tyr	Ser	Ile	Phe	275	Ala	Tyr	Phe	Gly	Ile	280	Tyr	Asn	Lys	Leu	Lys	285	Ser
Ile	Val	Ser	Val	290	Val	Ala	Val	Gln	Xaa	295	Arg	Lys	Val	Glu	Arg	300	Gly
Arg	Ile	Thr	Val	305	Arg	Thr	Asn	Cys	Leu	310	Leu	Ile	Ser	Ile	Ala	315	Ile
Arg	Arg	Met	Lys	320	Ser	Trp	Leu	Pro	Leu	325	Asp	Phe	Phe	Asn	Leu	330	Tyr
Ile	Phe	Gly	Val	335	Arg	Ser	Pro	Val	Thr	340	Gln	Ser	Met	Leu	Val	345	Arg
Ala	Asp	Met	Glu	350	His	Met	Ile	Gly	Met	355	Ser	Ser	Ala	Cys	Ser	360	Asn
Tyr	Ala	Ile	Cys	365	Gly	Trp	Leu	Asn	Asp	370	Asn	Phe	Arg	Lys	Glu	375	Ile
Pro	Leu	Leu	Tyr	380	Cys	Arg	Cys	Ser	Asp	385	Thr	Asn	Val	Ala	Leu	390	Asn
Gln	Glu	Leu	Leu	395	Gly	Cys	Asn	Val	Gln	400	Ala	Ala	Ala	Arg	Arg	405	Arg
Gly	His	Thr	Thr	410	Arg	Arg	Ile	Leu	Gln	415	Arg	Arg	Thr	Gln	Ala	420	Ala
Arg	Lys	Tyr	Gly	425	Ala	Arg	Ala	Val	Pro	430	Arg	Arg	Gly	Arg	Arg	435	Ser
Gly	Ala	Gly	Gly	440	Leu	His	Asp	Arg	His	445	His	Glu	Gly	Gly	Leu	450	Ala
Gly	Gly	His	Arg	455	His	His	His	His	His	460	Glu	Gly	Gly	Gly	Leu	465	Ala
Asn	Ile	Val	His	470	His												

<210> 2

<211> 326

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472034CD1

<400> 2

Met	Asp	Pro	Asn	Gln	Asp	Glu	Ile	Ser	Glu	Leu	Pro	Glu	Lys	Glu
1				5					10					15
Phe	Arg	Arg	Ser	Ile	Ile	Lys	Leu	Ile	Lys	Glu	Ala	Pro	Glu	Lys
				20					25					30
Gly	Ile	Pro	Gly	Leu	Glu	Glu	Ser	Gln	His	Trp	Ile	Ala	Leu	Pro
				35					40					45
Leu	Gly	Ile	Leu	Tyr	Leu	Leu	Ala	Leu	Val	Gly	Asn	Val	Thr	Ile
				50					55					60
Leu	Phe	Ile	Ile	Trp	Met	Asp	Pro	Ser	Leu	His	Gln	Ser	Met	Tyr
				65					70					75
Leu	Phe	Leu	Ser	Met	Leu	Ala	Ala	Ile	Asp	Leu	Val	Leu	Ala	Ser
				80					85					90
Ser	Thr	Ala	Pro	Lys	Ala	Leu	Ala	Val	Leu	Leu	Val	His	Ala	His
				95					100					105
Glu	Ile	Gly	Tyr	Ile	Val	Cys	Leu	Ile	Gln	Met	Phe	Phe	Ile	His
				110					115					120
Ala	Phe	Ser	Ser	Met	Glu	Ser	Gly	Val	Leu	Val	Ala	Met	Ala	Leu
				125					130					135
Asp	Arg	Tyr	Val	Ala	Ile	Cys	His	Pro	Leu	His	His	Ser	Thr	Ile
				140					145					150
Leu	His	Pro	Gly	Val	Ile	Gly	Arg	Ile	Gly	Met	Val	Val	Leu	Val
				155					160					165
Arg	Gly	Leu	Leu	Leu	Leu	Ile	Pro	Phe	Pro	Ile	Leu	Leu	Gly	Thr
				170					175					180
Leu	Ile	Phe	Cys	Gln	Ala	Thr	Ile	Ile	Gly	His	Ala	Tyr	Cys	Glu

His Met Ala Val	185	Lys Leu Ala Cys	190	Ser Glu Thr Thr Val	195
Arg Ala Tyr Gly	200	Leu Thr Met Ala Leu	205	Leu Val Ile Gly Leu	210
Val Leu Ala Ile	215	Gly Val Ser Tyr Ala	220	His Ile Leu Gln Ala	225
Leu Lys Val Pro	230	Gly Ser Glu Ala Arg	235	Leu Lys Ala Phe Ser	240
Cys Gly Ser His	245	Ile Cys Val Ile Leu	250	Val Phe Tyr Val Pro	255
Ile Phe Ser Phe	260	Leu Thr His Arg Phe	265	Gly His His Val Pro	270
His Val His Val	275	Leu Leu Ala Thr Arg	280	Tyr Leu Leu Met Pro	285
Ala Leu Asn Pro	290	Leu Val Tyr Gly Val	295	Lys Thr Gln Gln Ile	300
Gln Arg Val Leu	305	Arg Val Phe Thr Gln	310	Lys Asp	315
	320		325		

<210> 3

<211> 315

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472035CD1

<400> 3

Met Glu Thr Pro Ala	1	Ser Phe Leu Leu Val	10	Gly Ile Pro Gly Leu	15
Gln Ser Ser His Leu	20	Trp Leu Ala Ile Ser	25	Leu Ser Ala Met Tyr	30
Ile Ile Ala Leu Leu	35	Gly Asn Thr Ile Ile	40	Val Thr Ala Ile Trp	45
Met Asp Ser Thr Arg	50	His Glu Pro Met Tyr	55	Cys Phe Leu Cys Val	60
Leu Ala Ala Val Asp	65	Ile Val Met Ala Ser	70	Ser Val Val Pro Lys	75
Met Val Ser Ile Phe	80	Cys Ser Gly Asp Ser	85	Ser Ile Ser Phe Ser	90
Ala Cys Phe Thr Gln	95	Met Phe Phe Val His	100	Leu Ala Thr Ala Val	105
Glu Thr Gly Leu Leu	110	Leu Thr Met Ala Phe	115	Asp Arg Tyr Val Ala	120
Ile Cys Lys Pro Leu	125	His Tyr Lys Arg Ile	130	Leu Thr Pro Gln Val	135
Met Leu Gly Met Ser	140	Met Ala Ile Thr Ile	145	Arg Ala Ile Ile Ala	150
Ile Thr Pro Leu Ser	155	Trp Met Val Ser His	160	Leu Pro Phe Cys Gly	165
Ser Asn Val Val Val	170	His Ser Tyr Cys Glu	175	His Ile Ala Leu Ala	180
Arg Leu Ala Cys Ala	185	Asp Pro Val Pro Ser	190	Ser Leu Tyr Ser Leu	195
Ile Gly Ser Ser Leu	200	Met Val Gly Ser Asp	205	Val Ala Phe Ile Ala	210
Ala Ser Tyr Ile Leu	215	Ile Leu Lys Ala Val	220	Phe Gly Leu Ser Ser	225
Lys Thr Ala Gln Leu	230	Lys Ala Leu Ser Thr	235	Cys Gly Ser His Val	240
Gly Val Met Ala Leu	245	Tyr Tyr Leu Pro Gly	250	Met Ala Ser Ile Tyr	255
Ala Ala Trp Leu Gly	260	Gln Asp Val Val Pro	265	Leu His Thr Gln Val	270
Leu Leu Ala Asp Leu		Tyr Val Ile Ile Pro		Ala Thr Leu Asn Pro	

	275		280	285
Ile Ile Tyr Gly	Met Arg Thr Lys Gln	Leu Arg Glu Arg Ile	Trp	
	290	295	300	
Ser Tyr Leu Met	His Val Leu Phe Asp	His Ser Asn Leu Gly	Ser	
	305	310	315	

<210> 4
 <211> 314
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472036CD1

<400> 4

Met Ser Ala Ser Asn	Ile Thr Leu Thr His	Pro Thr Ala Phe Leu
1	5	10
Leu Val Gly Ile Pro	Gly Leu Glu His Leu	His Ile Trp Ile Ser
	20	25
Ile Pro Phe Cys Leu	Ala Tyr Thr Leu Ala	Leu Leu Gly Asn Cys
	35	40
Thr Leu Leu Leu Ile	Ile Gln Ala Asp Ala	Ala Leu His Glu Pro
	50	55
Met Tyr Leu Phe Leu	Ala Met Leu Ala Ala	Ile Asp Leu Val Leu
	65	70
Ser Ser Ser Ala Leu	Pro Lys Met Leu Ala	Ile Phe Trp Phe Arg
	80	85
Asp Arg Glu Ile Asn	Phe Phe Ala Cys Leu	Ala Gln Met Phe Phe
	95	100
Leu His Ser Phe Ser	Ile Met Glu Ser Ala	Val Leu Leu Ala Met
	110	115
Ala Phe Asp Arg Tyr	Val Ala Ile Cys Lys	Pro Leu His Tyr Thr
	125	130
Lys Val Leu Thr Gly	Ser Leu Ile Thr Lys	Ile Gly Met Ala Ala
	140	145
Val Ala Arg Ala Val	Thr Leu Met Thr Pro	Leu Pro Phe Leu Leu
	155	160
Arg Cys Phe His Tyr	Cys Arg Gly Pro Val	Ile Ala His Cys Tyr
	170	175
Cys Glu His Met Ala	Val Val Arg Leu Ala	Cys Gly Asp Thr Ser
	185	190
Phe Asn Asn Ile Tyr	Gly Ile Ala Val Ala	Met Phe Ile Val Val
	200	205
Leu Asp Leu Leu Leu	Val Ile Leu Ser Tyr	Ile Phe Ile Leu Gln
	215	220
Ala Val Leu Leu Leu	Ala Ser Gln Glu Ala	Arg Tyr Lys Ala Phe
	230	235
Gly Thr Cys Val Ser	His Ile Gly Ala Ile	Leu Ala Phe Tyr Thr
	245	250
Thr Val Val Ile Ser	Ser Val Met His Arg	Val Ala Arg His Ala
	260	265
Ala Pro His Val His	Ile Leu Leu Ala Asn	Phe Tyr Leu Leu Phe
	275	280
Pro Pro Met Val Asn	Pro Ile Ile Tyr Gly	Val Lys Thr Lys Gln
	290	295
Ile Arg Glu Ser Ile	Leu Gly Val Phe Pro	Arg Lys Asp Met
	305	310

<210> 5
 <211> 321
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature

<223> Incyte ID No: 7472037CD1

<400> 5

Met	Ala	His	Gln	Ala	Pro	Glu	Lys	Gln	Gln	Asp	Asn	Gly	Thr	Trp
1				5					10					15
Leu	Val	Thr	Glu	Phe	Leu	Leu	Val	Gly	Phe	Ser	Asn	Leu	Pro	Glu
				20					25					30
Leu	Arg	Pro	Thr	Leu	Phe	Ile	Leu	Phe	Leu	Leu	Thr	Tyr	Leu	Val
				35					40					45
Thr	Leu	Ser	Gly	Asn	Ala	Thr	Ile	Ile	Thr	Ile	Ile	Gln	Val	Asp
				50					55					60
Arg	Thr	Leu	His	Thr	Pro	Met	Tyr	Arg	Phe	Leu	Ala	Val	Leu	Ser
				65					70					75
Leu	Ser	Glu	Thr	Cys	Tyr	Thr	Leu	Val	Thr	Ile	Pro	Asn	Met	Leu
				80					85					90
Ala	His	Leu	Leu	Met	Glu	Ser	Gln	Ala	Ile	Ser	Ile	Ala	Gly	Cys
				95					100					105
Arg	Ala	Gln	Met	Phe	Phe	Phe	Leu	Gly	Leu	Gly	Cys	Ser	His	Cys
				110					115					120
Phe	Leu	Leu	Thr	Leu	Met	Gly	Tyr	Asp	Arg	Tyr	Val	Ala	Ile	Cys
				125					130					135
His	Pro	Leu	Arg	Tyr	Ser	Val	Ile	Met	Arg	Pro	Thr	Val	Cys	Leu
				140					145					150
Cys	Leu	Gly	Ala	Leu	Val	Phe	Cys	Ser	Gly	Phe	Ser	Val	Ala	Leu
				155					160					165
Ile	Glu	Thr	Cys	Met	Ile	Phe	Ser	Ser	Pro	Phe	Cys	Gly	Ala	Gly
				170					175					180
His	Val	Glu	His	Phe	Phe	Cys	Asp	Ile	Ala	Pro	Val	Leu	Lys	Leu
				185					190					195
Ser	Cys	Asp	Glu	Ser	Ser	Leu	Lys	Gly	Leu	Gly	Ile	Phe	Phe	Leu
				200					205					210
Ser	Ile	Leu	Val	Val	Leu	Val	Ser	Phe	Leu	Phe	Ile	Leu	Leu	Ser
				215					220					225
Tyr	Ala	Phe	Ile	Val	Ala	Ala	Ile	Val	Arg	Ile	Pro	Ser	Ala	Ser
				230					235					240
Gly	Arg	Arg	Lys	Ala	Phe	Ser	Thr	Cys	Ala	Ala	His	Leu	Thr	Val
				245					250					255
Val	Ile	Val	His	Phe	Gly	Cys	Ala	Ser	Ile	Ile	Tyr	Leu	Arg	Pro
				260					265					270
Asp	Ser	Gly	Ala	Asn	Pro	Ser	Gln	Asp	Arg	Leu	Val	Ala	Val	Phe
				275					280					285
Tyr	Thr	Val	Val	Thr	Pro	Leu	Leu	Asn	Pro	Val	Val	Tyr	Thr	Leu
				290					295					300
Arg	Asn	Lys	Glu	Val	Arg	Val	Ala	Leu	Arg	Lys	Asn	Leu	Ala	Arg
				305					310					315
Gly	Cys	Gly	Ala	Phe	Lys									
				320										

<210> 6

<211> 331

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472039CD1

<400> 6

Met	Ser	Pro	Asp	Gly	Asn	His	Ser	Ser	Asp	Pro	Thr	Glu	Phe	Val
1				5					10					15
Leu	Ala	Gly	Leu	Pro	Asn	Leu	Asn	Ser	Ala	Arg	Val	Glu	Leu	Phe
				20					25					30
Ser	Val	Phe	Leu	Leu	Val	Tyr	Leu	Leu	Asn	Leu	Thr	Gly	Asn	Val
				35					40					45
Leu	Ile	Val	Gly	Val	Val	Arg	Ala	Asp	Thr	Arg	Leu	Gln	Thr	Pro
				50					55					60
Met	Tyr	Phe	Phe	Leu	Gly	Asn	Leu	Ser	Cys	Leu	Glu	Ile	Leu	Leu

Thr	Ser	Val	Ile	65	Pro	Lys	Met	Leu	70	Ser	Asn	Phe	Leu	Ser	Arg	75
				80					85							90
Gln	His	Thr	Ile	Ser	Phe	Ala	Ala	Cys	Ile	Thr	Gln	Phe	Tyr	Phe		
				95					100							105
Tyr	Phe	Phe	Leu	Gly	Ala	Ser	Glu	Phe	Leu	Leu	Ala	Val	Met			
				110					115							120
Ser	Ala	Asp	Arg	Tyr	Leu	Ala	Ile	Cys	His	Pro	Leu	Arg	Tyr	Pro		
				125					130							135
Leu	Leu	Met	Ser	Gly	Ala	Val	Cys	Phe	Arg	Val	Ala	Leu	Ala	Cys		
				140					145							150
Trp	Val	Gly	Gly	Leu	Val	Pro	Val	Leu	Gly	Pro	Thr	Val	Ala	Val		
				155					160							165
Ala	Leu	Leu	Pro	Phe	Cys	Lys	Gln	Gly	Ala	Val	Val	Gln	His	Phe		
				170					175							180
Phe	Cys	Asp	Ser	Gly	Pro	Leu	Leu	Arg	Leu	Ala	Cys	Thr	Asn	Thr		
				185					190							195
Lys	Lys	Leu	Glu	Glu	Thr	Asp	Phe	Val	Leu	Ala	Ser	Leu	Val	Ile		
				200					205							210
Val	Ser	Ser	Leu	Leu	Ile	Thr	Ala	Val	Ser	Tyr	Gly	Leu	Ile	Val		
				215					220							225
Leu	Ala	Val	Leu	Ser	Ile	Pro	Ser	Ala	Ser	Gly	Arg	Gln	Lys	Ala		
				230					235							240
Phe	Ser	Thr	Cys	Thr	Ser	His	Leu	Ile	Val	Val	Thr	Leu	Phe	Tyr		
				245					250							255
Gly	Ser	Ala	Ile	Phe	Leu	Tyr	Val	Arg	Pro	Ser	Gln	Ser	Gly	Ser		
				260					265							270
Val	Asp	Thr	Asn	Trp	Ala	Val	Thr	Val	Ile	Thr	Thr	Phe	Val	Thr		
				275					280							285
Pro	Leu	Leu	Asn	Pro	Phe	Ile	Tyr	Ala	Leu	Arg	Asn	Glu	Gln	Val		
				290					295							300
Lys	Glu	Ala	Leu	Lys	Asp	Met	Phe	Arg	Lys	Val	Val	Ala	Gly	Val		
				305					310							315
Leu	Gly	Asn	Leu	Leu	Leu	Asp	Lys	Cys	Leu	Ser	Glu	Lys	Ala	Val		
				320					325							330

Lys

<210> 7
 <211> 337
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472040CD1

<400> 7
 Met Gly Asn Asp Ser Val Ser Tyr Glu Tyr Gly Asp Tyr Ser Asp
 1 5 10 15
 Leu Ser Asp Arg Pro Val Asp Cys Leu Asp Gly Ala Cys Leu Ala
 20 25 30
 Ile Asp Pro Leu Arg Val Ala Pro Leu Pro Leu Tyr Ala Ala Ile
 35 40 45
 Phe Leu Val Gly Val Pro Gly Asn Ala Met Val Ala Trp Val Ala
 50 55 60
 Gly Lys Val Ala Arg Arg Arg Val Gly Ala Thr Trp Leu Leu His
 65 70 75
 Leu Ala Val Ala Asp Leu Leu Cys Cys Leu Ser Leu Pro Ile Leu
 80 85 90
 Ala Val Pro Ile Ala Arg Gly Gly His Trp Pro Tyr Gly Ala Val
 95 100 105
 Gly Cys Arg Ala Leu Pro Ser Ile Ile Leu Leu Thr Met Tyr Ala
 110 115 120
 Ser Val Leu Leu Leu Ala Ala Leu Ser Ala Asp Leu Cys Phe Leu
 125 130 135
 Ala Leu Gly Pro Ala Trp Trp Ser Thr Val Gln Arg Ala Cys Gly

Val	Gln	Val	Ala	Cys	Gly	Ala	Ala	Trp	Thr	Leu	Ala	Leu	Leu	Leu	140	145	150
Thr	Val	Pro	Ser	Ala	Ile	Tyr	Arg	Arg	Leu	His	Gln	Glu	His	Phe	155	160	165
Pro	Ala	Arg	Leu	Gln	Cys	Val	Val	Asp	Tyr	Gly	Gly	Ser	Ser	Ser	170	175	180
Thr	Glu	Asn	Ala	Val	Thr	Ala	Ile	Arg	Phe	Leu	Phe	Gly	Phe	Leu	185	190	195
Gly	Pro	Leu	Val	Ala	Val	Ala	Ser	Cys	His	Ser	Ala	Leu	Leu	Cys	200	205	210
Trp	Ala	Ala	Arg	Arg	Cys	Arg	Pro	Leu	Gly	Thr	Ala	Ile	Val	Val	215	220	225
Gly	Phe	Phe	Val	Cys	Trp	Ala	Pro	Tyr	His	Leu	Leu	Gly	Leu	Val	230	235	240
Leu	Thr	Val	Ala	Ala	Pro	Asn	Ser	Ala	Leu	Leu	Ala	Arg	Ala	Leu	245	250	255
Arg	Ala	Glu	Pro	Leu	Ile	Val	Gly	Leu	Ala	Leu	Ala	His	Ser	Cys	260	265	270
Leu	Asn	Pro	Met	Leu	Phe	Leu	Tyr	Phe	Gly	Arg	Ala	Gln	Leu	Arg	275	280	285
Arg	Ser	Leu	Pro	Ala	Ala	Cys	His	Trp	Ala	Leu	Arg	Glu	Ser	Gln	290	295	300
Gly	Gln	Asp	Glu	Ser	Val	Asp	Ser	Lys	Lys	Ser	Thr	Ser	His	Asp	305	310	315
Leu	Val	Ser	Glu	Met	Glu	Val									320	325	330
															335		

<210> 8

<211> 1473

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4250893CD1

<400> 8

Met	Ala	Gly	Gly	Ala	Trp	Gly	Arg	Leu	Ala	Cys	Tyr	Leu	Glu	Phe	1	5	10	15
Leu	Lys	Lys	Glu	Glu	Leu	Lys	Glu	Phe	Gln	Leu	Leu	Leu	Ala	Asn	20	25	30	35
Lys	Ala	His	Ser	Arg	Ser	Ser	Ser	Gly	Glu	Thr	Pro	Ala	Gln	Pro	35	40	45	50
Glu	Lys	Thr	Ser	Gly	Met	Glu	Val	Ala	Ser	Tyr	Leu	Val	Ala	Gln	50	55	60	65
Tyr	Gly	Glu	Gln	Arg	Ala	Trp	Asp	Leu	Ala	Leu	His	Thr	Trp	Glu	65	70	75	80
Gln	Met	Gly	Leu	Arg	Ser	Leu	Cys	Ala	Gln	Ala	Gln	Glu	Gly	Ala	80	85	90	95
Gly	His	Ser	Pro	Ser	Phe	Pro	Tyr	Ser	Pro	Ser	Glu	Pro	His	Leu	95	100	105	110
Gly	Ser	Pro	Ser	Gln	Pro	Thr	Ser	Thr	Ala	Val	Leu	Met	Pro	Trp	110	115	120	125
Ile	His	Glu	Leu	Pro	Ala	Gly	Cys	Thr	Gln	Gly	Ser	Glu	Arg	Arg	125	130	135	140
Val	Leu	Arg	Gln	Leu	Pro	Asp	Thr	Ser	Gly	Arg	Arg	Trp	Arg	Glu	140	145	150	155
Ile	Ser	Ala	Ser	His	Val	Tyr	Gln	Ala	Leu	Pro	Ser	Ser	Pro	Asp	155	160	165	170
His	Glu	Ser	Pro	Ser	Gln	Glu	Ser	Pro	Asn	Ala	Pro	Thr	Ser	Thr	170	175	180	185
Ala	Val	Leu	Gly	Ser	Trp	Gly	Ser	Pro	Pro	Gln	Pro	Ser	Leu	Ala	185	190	195	200
Pro	Arg	Glu	Gln	Glu	Ala	Pro	Gly	Thr	Gln	Trp	Pro	Leu	Asp	Glu	200	205	210	215
Thr	Ser	Gly	Ile	Tyr	Tyr	Thr	Glu	Ile	Arg	Glu	Arg	Glu	Arg	Glu	215	220	225	230

Lys	Ser	Glu	Lys	215	Gly	Arg	Pro	Pro	Trp	220	Ala	Ala	Val	Val	Gly	Thr	225
				230						235							240
Pro	Pro	Gln	Ala	245	His	Thr	Ser	Leu	Gln	250	Pro	His	His	His	Pro	Trp	255
Glu	Pro	Ser	Val	260	Arg	Glu	Ser	Leu	Cys	265	Ser	Thr	Trp	Pro	Trp	Lys	270
Asn	Glu	Asp	Phe	275	Asn	Gln	Lys	Phe	Thr	280	Gln	Leu	Leu	Leu	Leu	Gln	285
Arg	Pro	His	Pro	290	Arg	Ser	Gln	Asp	Pro	295	Leu	Val	Lys	Arg	Ser	Trp	300
Pro	Asp	Tyr	Val	305	Glu	Glu	Asn	Arg	Gly	310	His	Leu	Ile	Glu	Ile	Arg	315
Asp	Leu	Phe	Gly	320	Pro	Gly	Leu	Asp	Thr	325	Gln	Glu	Pro	Arg	Ile	Val	330
Ile	Leu	Gln	Gly	335	Ala	Ala	Gly	Ile	Gly	340	Lys	Ser	Thr	Leu	Ala	Arg	345
Gln	Val	Lys	Glu	350	Ala	Trp	Gly	Arg	Gly	355	Gln	Leu	Tyr	Gly	Asp	Arg	360
Phe	Gln	His	Val	365	Phe	Tyr	Phe	Ser	Cys	370	Arg	Glu	Leu	Ala	Gln	Ser	375
Lys	Val	Val	Ser	380	Leu	Ala	Glu	Leu	Ile	385	Gly	Lys	Asp	Gly	Thr	Ala	390
Thr	Pro	Ala	Pro	395	Ile	Arg	Gln	Ile	Leu	400	Ser	Arg	Pro	Glu	Arg	Leu	405
Leu	Phe	Ile	Leu	410	Asp	Gly	Val	Asp	Glu	415	Pro	Gly	Trp	Val	Leu	Gln	420
Glu	Pro	Ser	Ser	425	Glu	Leu	Cys	Leu	His	430	Trp	Ser	Gln	Pro	Gln	Pro	435
Ala	Asp	Ala	Leu	440	Leu	Gly	Ser	Leu	Leu	445	Gly	Lys	Thr	Ile	Leu	Pro	450
Glu	Ala	Ser	Phe	455	Leu	Ile	Thr	Ala	Arg	460	Thr	Thr	Ala	Leu	Gln	Asn	465
Leu	Ile	Pro	Ser	470	Leu	Glu	Gln	Ala	Arg	475	Trp	Val	Glu	Val	Leu	Gly	480
Phe	Ser	Glu	Ser	485	Ser	Arg	Lys	Glu	Tyr	490	Phe	Tyr	Arg	Tyr	Phe	Thr	495
Asp	Glu	Arg	Gln	500	Ala	Ile	Arg	Ala	Phe	505	Arg	Leu	Val	Lys	Ser	Asn	510
Lys	Glu	Leu	Trp	515	Ala	Leu	Cys	Leu	Val	520	Pro	Trp	Val	Ser	Trp	Leu	525
Ala	Cys	Thr	Cys	530	Leu	Met	Gln	Gln	Met	535	Lys	Arg	Lys	Glu	Lys	Leu	540
Thr	Leu	Thr	Ser	545	Lys	Thr	Thr	Thr	Thr	550	Leu	Cys	Leu	His	Tyr	Leu	555
Ala	Gln	Ala	Leu	560	Gln	Ala	Gln	Pro	Leu	565	Gly	Pro	Gln	Leu	Arg	Asp	570
Leu	Cys	Ser	Leu	575	Ala	Ala	Glu	Gly	Ile	580	Trp	Gln	Lys	Lys	Thr	Leu	585
Phe	Ser	Pro	Asp	590	Asp	Leu	Arg	Lys	His	595	Gly	Leu	Asp	Gly	Ala	Ile	600
Ile	Ser	Thr	Phe	605	Leu	Lys	Met	Gly	Ile	610	Leu	Gln	Glu	His	Pro	Ile	615
Pro	Leu	Ser	Tyr	620	Ser	Phe	Ile	His	Leu	625	Cys	Phe	Gln	Glu	Phe	Phe	630
Ala	Ala	Met	Ser	635	Val	Leu	Glu	Asp	Glu	640	Lys	Gly	Arg	Gly	Lys	Lys	645
His	Ser	Asn	Cys	650	Ile	Ile	Asp	Leu	Glu	655	Lys	Thr	Leu	Glu	Ala	Tyr	660
Gly	Ile	His	Gly	665	Leu	Phe	Gly	Ala	Ser	670	Thr	Thr	Arg	Phe	Leu	Leu	675
Gly	Leu	Leu	Ser	680	Asp	Glu	Gly	Glu	Arg	685	Glu	Met	Glu	Asn	Ile	Phe	690
His	Cys	Arg	Leu	695	Ser	Gln	Gly	Arg	Asn	700	Leu	Met	Gln	Trp	Val	Pro	705
Ser	Leu	Gln	Leu	710	Leu	Leu	Gln	Pro	His	715	Ser	Leu	Glu	Ser	Leu	His	720

Cys	Leu	Tyr	Glu	Thr	Arg	Asn	Lys	Thr	Phe	Leu	Thr	Gln	Val	Met
				725					730					735
Ala	His	Phe	Glu	Glu	Met	Gly	Met	Cys	Val	Glu	Thr	Asp	Met	Glu
				740					745					750
Leu	Leu	Val	Cys	Thr	Phe	Cys	Ile	Lys	Phe	Ser	Arg	His	Val	Lys
				755					760					765
Lys	Leu	Gln	Leu	Ile	Glu	Gly	Arg	Gln	His	Arg	Ser	Thr	Trp	Ser
				770					775					780
Pro	Thr	Met	Val	Val	Leu	Phe	Arg	Trp	Val	Pro	Val	Thr	Asp	Ala
				785					790					795
Tyr	Trp	Gln	Ile	Leu	Phe	Ser	Val	Leu	Lys	Val	Thr	Arg	Asn	Leu
				800					805					810
Lys	Glu	Leu	Asp	Leu	Ser	Gly	Asn	Ser	Leu	Ser	His	Ser	Ala	Val
				815					820					825
Lys	Ser	Leu	Cys	Lys	Thr	Leu	Arg	Arg	Pro	Arg	Cys	Leu	Leu	Glu
				830					835					840
Thr	Leu	Arg	Leu	Ala	Gly	Cys	Gly	Leu	Thr	Ala	Glu	Asp	Cys	Lys
				845					850					855
Asp	Leu	Ala	Phe	Gly	Leu	Arg	Ala	Asn	Gln	Thr	Leu	Thr	Glu	Leu
				860					865					870
Asp	Leu	Ser	Phe	Asn	Val	Leu	Thr	Asp	Ala	Gly	Ala	Lys	His	Leu
				875					880					885
Cys	Gln	Arg	Leu	Arg	Gln	Pro	Ser	Cys	Lys	Leu	Gln	Arg	Leu	Gln
				890					895					900
Leu	Val	Ser	Cys	Gly	Leu	Thr	Ser	Asp	Cys	Cys	Gln	Asp	Leu	Ala
				905					910					915
Ser	Val	Leu	Ser	Ala	Ser	Pro	Ser	Leu	Lys	Glu	Leu	Asp	Leu	Gln
				920					925					930
Gln	Asn	Asn	Leu	Asp	Asp	Val	Gly	Val	Arg	Leu	Leu	Cys	Glu	Gly
				935					940					945
Leu	Arg	His	Pro	Ala	Cys	Lys	Leu	Ile	Arg	Leu	Gly	Leu	Asp	Gln
				950					955					960
Thr	Thr	Leu	Ser	Asp	Glu	Met	Arg	Gln	Glu	Leu	Arg	Ala	Leu	Glu
				965					970					975
Gln	Glu	Lys	Pro	Gln	Leu	Leu	Ile	Phe	Ser	Arg	Arg	Lys	Pro	Ser
				980					985					990
Val	Met	Thr	Pro	Thr	Glu	Gly	Leu	Asp	Thr	Gly	Glu	Met	Ser	Asn
				995					1000					1005
Ser	Thr	Ser	Ser	Leu	Lys	Arg	Gln	Arg	Leu	Gly	Ser	Glu	Arg	Ala
				1010					1015					1020
Ala	Ser	His	Val	Ala	Gln	Ala	Asn	Leu	Lys	Leu	Leu	Asp	Val	Ser
				1025					1030					1035
Lys	Ile	Phe	Pro	Ile	Ala	Glu	Ile	Ala	Glu	Glu	Ser	Ser	Pro	Glu
				1040					1045					1050
Val	Val	Pro	Val	Glu	Leu	Leu	Cys	Val	Pro	Ser	Pro	Ala	Ser	Gln
				1055					1060					1065
Gly	Asp	Leu	His	Thr	Lys	Pro	Leu	Gly	Thr	Asp	Asp	Asp	Phe	Trp
				1070					1075					1080
Gly	Pro	Thr	Gly	Pro	Val	Ala	Thr	Glu	Val	Val	Asp	Lys	Glu	Lys
				1085					1090					1095
Asn	Leu	Tyr	Arg	Val	His	Phe	Pro	Val	Ala	Gly	Ser	Tyr	Arg	Trp
				1100					1105					1110
Pro	Asn	Thr	Gly	Leu	Cys	Phe	Val	Met	Arg	Glu	Ala	Val	Thr	Val
				1115					1120					1125
Glu	Ile	Glu	Phe	Cys	Val	Trp	Asp	Gln	Phe	Leu	Gly	Glu	Ile	Asn
				1130					1135					1140
Pro	Gln	His	Ser	Trp	Met	Val	Ala	Gly	Pro	Leu	Leu	Asp	Ile	Lys
				1145					1150					1155
Ala	Glu	Pro	Gly	Ala	Val	Glu	Ala	Val	His	Leu	Pro	His	Phe	Val
				1160					1165					1170
Ala	Leu	Gln	Gly	Gly	His	Val	Asp	Thr	Ser	Leu	Phe	Gln	Met	Ala
				1175					1180					1185
His	Phe	Lys	Glu	Glu	Gly	Met	Leu	Leu	Glu	Lys	Pro	Ala	Arg	Val
				1190					1195					1200
Glu	Leu	His	His	Ile	Val	Leu	Glu	Asn	Pro	Ser	Phe	Ser	Pro	Leu
				1205					1210					1215
Gly	Val	Leu	Leu	Lys	Met	Ile	His	Asn	Ala	Leu	Arg	Phe	Ile	Pro

```

1220          1225          1230
Val Thr Ser Val Val Leu Leu Tyr His Arg Val His Pro Glu Glu
1235          1240          1245
Val Thr Phe His Leu Tyr Leu Ile Pro Ser Asp Cys Ser Ile Arg
1250          1255          1260
Lys Ala Ile Asp Asp Leu Glu Met Lys Phe Gln Phe Val Arg Ile
1265          1270          1275
His Lys Pro Pro Pro Leu Thr Pro Leu Tyr Met Gly Cys Arg Tyr
1280          1285          1290
Thr Val Ser Gly Ser Gly Ser Gly Met Leu Glu Ile Leu Pro Lys
1295          1300          1305
Glu Leu Glu Leu Cys Tyr Arg Ser Pro Gly Glu Asp Gln Leu Phe
1310          1315          1320
Ser Glu Ser Tyr Val Gly His Leu Gly Ser Gly Ile Arg Leu Gln
1325          1330          1335
Val Lys Asp Lys Lys Asp Glu Thr Leu Val Trp Glu Ala Leu Val
1340          1345          1350
Lys Pro Gly Asp Leu Met Pro Ala Thr Thr Leu Ile Pro Pro Ala
1355          1360          1365
Arg Ile Ala Val Pro Ser Pro Leu Asp Ala Pro Gln Leu Leu His
1370          1375          1380
Phe Val Asp Gln Tyr Arg Glu Gln Leu Ile Ala Arg Val Thr Ser
1385          1390          1395
Val Glu Val Val Leu Asp Lys Leu His Gly Gln Val Leu Ser Gln
1400          1405          1410
Glu Gln Tyr Glu Arg Val Leu Ala Glu Asn Thr Arg Pro Ser Gln
1415          1420          1425
Met Arg Lys Leu Phe Ser Leu Ser Gln Ser Trp Asp Arg Lys Cys
1430          1435          1440
Lys Asp Gly Leu Tyr Gln Ala Leu Lys Glu Thr His Pro His Leu
1445          1450          1455
Ile Met Glu Leu Trp Glu Lys Gly Ser Lys Lys Gly Leu Leu Pro
1460          1465          1470
Leu Ser Ser

```

<210> 9
 <211> 328
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6726656CD1

```

<400> 9
Met Lys Leu Trp Met Glu Ser His Leu Ile Val Pro Glu Thr Arg
1      5      10      15
Pro Ser Pro Arg Met Met Ser Asn Gln Thr Leu Val Thr Glu Phe
20     25     30
Ile Leu Gln Gly Phe Ser Glu His Pro Glu Tyr Arg Val Phe Leu
35     40     45
Phe Ser Cys Phe Leu Phe Leu Tyr Ser Gly Ala Leu Thr Gly Asn
50     55     60
Val Leu Ile Thr Leu Ala Ile Thr Phe Asn Pro Gly Leu His Ala
65     70     75
Pro Met Tyr Phe Phe Leu Leu Asn Leu Ala Thr Met Asp Ile Ile
80     85     90
Cys Thr Ser Ser Ile Met Pro Lys Ala Leu Ala Ser Leu Val Ser
95     100    105
Glu Glu Ser Ser Ile Ser Tyr Gly Gly Cys Met Ala Gln Leu Tyr
110    115    120
Phe Leu Thr Trp Ala Ala Ser Ser Glu Leu Leu Leu Thr Val
125    130    135
Met Ala Tyr Asp Arg Tyr Ala Ala Ile Cys His Pro Leu His Tyr
140    145    150
Ser Ser Met Met Ser Lys Val Phe Cys Ser Gly Leu Ala Thr Ala

```

Val Trp Leu Leu	155	Ala Val Asn Thr	160	Ala Ile His Thr Gly	165
Met Leu Arg Leu	170	Phe Cys Gly Pro	175	Asn Val Ile Ile His	180
Phe Cys Glu Val	185	Pro Leu Leu Leu	190	Ser Cys Ser Ser	195
Tyr Val Asn Gly	200	Val Met Ile Val Leu	205	Ala Asp Ala Phe Tyr	210
Ile Val Asn Phe	215	Leu Met Thr Ile Ala	220	Ser Tyr Gly Phe Ile	225
Ser Ser Ile Leu	230	Val Lys Thr Ala	235	Gly Arg Gln Lys	240
Phe Ser Thr Cys	245	Ser Ser His Leu Thr	250	Val Val Cys Met Tyr	255
Thr Ala Val Phe	260	Ala Tyr Ile Ser	265	Val Ser Gly Tyr	270
Ala Gly Lys Ser	275	Lys Leu Ala Gly Leu	280	Leu Tyr Thr Val Leu	285
Pro Thr Leu Asn	290	Pro Leu Ile Tyr Thr	295	Leu Arg Asn Lys Glu	300
Lys Ala Ala Leu	305	Arg Lys Leu Phe Pro	310	Phe Phe Arg Asn	315
	320		325		

<210> 10

<211> 384

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472062CD1

<400> 10

Met Asn Val Leu Leu	1	Ala Asp Ser Asn Ser	10	Asn Lys Lys Ile Val	15
His Lys His Ile Cys	5	Ser Leu Gln Ser Ala	20	Pro Lys Thr Thr Asn	25
Leu Gln Pro Ser Ile	20	Ser Asp Ile Leu Leu	25	Ser Val Glu Ser Asn	30
Asp Arg Lys Asn Val	35	Ser Lys Ile Lys Gly	40	Asp Cys Phe Asn Thr	45
Arg Val Ser Cys Asp	50	Ser Lys Ile Thr Ser	55	Met Glu Asn Asn Thr	60
Glu Val Ser Glu Phe	65	Ile Leu Leu Gly Leu	70	Thr Asn Ala Pro Glu	75
Leu Gln Val Pro Leu	80	Phe Ile Met Phe Thr	85	Leu Ile Tyr Leu Ile	90
Thr Leu Thr Gly Asn	95	Leu Gly Met Ile Ile	100	Leu Ile Leu Leu Asp	105
Ser His Leu His Thr	110	Pro Met Tyr Phe Phe	115	Leu Ser Asn Leu Ser	120
Leu Ala Gly Ile Gly	125	Tyr Ser Ser Ala Val	130	Thr Pro Lys Val Leu	135
Thr Gly Leu Leu Ile	140	Glu Asp Lys Ala Ile	145	Ser Tyr Ser Ala Cys	150
Ala Ala Gln Met Phe	155	Phe Cys Ala Val Phe	160	Ala Thr Val Glu Asn	165
Tyr Leu Leu Ser Ser	170	Met Ala Tyr Asp Arg	175	Tyr Ala Ala Val Cys	180
Asn Pro Leu His Tyr	185	Thr Thr Thr Met Thr	190	Thr Arg Val Cys Ala	195
Cys Leu Ala Ile Gly	200	Cys Tyr Val Ile Gly	205	Phe Leu Asn Ala Ser	210
Ile Gln Ile Gly Asp	215	Thr Phe Arg Leu Ser	220	Phe Cys Met Ser Asn	225
Val Ile His His Phe	230	Phe Cys Asp Lys Pro	235	Ala Val Ile Thr Leu	240

Thr	Cys	Ser	Glu	245	Lys	His	Ile	Ser	Glu	250	Leu	Ile	Leu	Val	Leu	255
				260						265						270
Ser	Ser	Phe	Asn	275	Val	Phe	Phe	Ala	Leu	280	Leu	Val	Thr	Leu	Ile	285
Tyr	Leu	Phe	Ile	290	Leu	Ile	Thr	Ile	Leu	295	Lys	Arg	His	Thr	Gly	300
Gly	Tyr	Gln	Lys	305	Pro	Leu	Ser	Thr	Cys	310	Gly	Ser	His	Leu	Ile	315
Ile	Phe	Leu	Phe	320	Tyr	Ile	Thr	Val	Ile	325	Ile	Met	Tyr	Ile	Arg	330
Ser	Ser	Ser	His	335	Ser	Met	Asp	Thr	Asp	340	Lys	Ile	Ala	Ser	Val	345
Tyr	Thr	Met	Ile	350	Ile	Pro	Met	Leu	Ser	355	Pro	Ile	Val	Tyr	Thr	360
Arg	Asn	Lys	Asp	365	Val	Lys	Asn	Ala	Phe	370	Met	Lys	Val	Val	Glu	375
Ala	Lys	Tyr	Ser	380	Leu	Asp	Ser	Val	Phe							

<210> 11

<211> 419

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472067CD1

<400> 11

Met	Leu	Ala	Ala	Ala	Phe	Ala	Asp	Ser	Asn	Ser	Ser	Ser	Met	Asn		
1				5					10					15		
Val	Ser	Phe	Ala	His	Leu	His	Phe	Ala	Gly	Gly	Tyr	Leu	Pro	Ser		
				20					25					30		
Asp	Ser	Gln	Asp	Trp	Arg	Thr	Ile	Ile	Pro	Ala	Leu	Leu	Val	Ala		
				35					40					45		
Val	Cys	Leu	Val	Gly	Phe	Val	Gly	Asn	Leu	Cys	Val	Ile	Gly	Ile		
				50					55					60		
Leu	Leu	His	Asn	Ala	Trp	Lys	Gly	Lys	Pro	Ser	Met	Ile	His	Ser		
				65					70					75		
Leu	Ile	Leu	Asn	Leu	Ser	Leu	Ala	Asp	Leu	Ser	Leu	Leu	Leu	Phe		
				80					85					90		
Ser	Ala	Pro	Ile	Arg	Ala	Thr	Ala	Tyr	Ser	Lys	Ser	Val	Trp	Asp		
				95					100					105		
Leu	Gly	Trp	Phe	Val	Cys	Lys	Ser	Ser	Asp	Trp	Phe	Ile	His	Thr		
				110					115					120		
Cys	Met	Ala	Ala	Lys	Ser	Leu	Thr	Ile	Val	Val	Val	Ala	Lys	Val		
				125					130					135		
Cys	Phe	Met	Tyr	Ala	Ser	Asp	Pro	Ala	Lys	Gln	Val	Ser	Ile	His		
				140					145					150		
Asn	Tyr	Thr	Ile	Trp	Ser	Val	Leu	Val	Ala	Ile	Trp	Thr	Val	Ala		
				155					160					165		
Ser	Leu	Leu	Pro	Leu	Pro	Glu	Trp	Phe	Phe	Ser	Thr	Ile	Arg	His		
				170					175					180		
His	Glu	Gly	Val	Glu	Met	Cys	Leu	Val	Asp	Val	Pro	Ala	Val	Ala		
				185					190					195		
Glu	Glu	Phe	Met	Ser	Met	Phe	Gly	Lys	Leu	Tyr	Pro	Leu	Leu	Ala		
				200					205					210		
Phe	Gly	Leu	Pro	Leu	Phe	Phe	Ala	Ser	Phe	Tyr	Phe	Trp	Arg	Ala		
				215					220					225		
Tyr	Asp	Gln	Cys	Lys	Lys	Arg	Gly	Thr	Lys	Thr	Gln	Asn	Leu	Arg		
				230					235					240		
Asn	Gln	Ile	Arg	Ser	Lys	Gln	Val	Thr	Val	Met	Leu	Leu	Ser	Ile		
				245					250					255		
Ala	Ile	Ile	Ser	Ala	Leu	Leu	Trp	Leu	Pro	Glu	Trp	Val	Ala	Trp		
				260					265					270		
Leu	Trp	Val	Trp	His	Leu	Lys	Ala	Ala	Gly	Pro	Ala	Pro	Pro	Gln		

	275		280		285
Gly Phe Ile Ala	Leu Ser Gln Val Leu	Met Phe Ser Ile Ser	Ser		
	290		295		300
Ala Asn Pro Leu	Ile Phe Leu Val Met	Ser Glu Glu Phe Arg	Glu		
	305		310		315
Gly Leu Lys Gly	Val Trp Lys Trp Met	Ile Thr Lys Lys Pro	Pro		
	320		325		330
Thr Val Ser Glu	Ser Gln Glu Thr Pro	Ala Gly Asn Ser Glu	Gly		
	335		340		345
Leu Pro Asp Lys	Val Pro Ser Pro Glu	Ser Pro Ala Ser Ile	Pro		
	350		355		360
Glu Lys Glu Lys	Pro Ser Ser Pro Ser	Ser Gly Lys Gly Lys	Thr		
	365		370		375
Glu Lys Ala Glu	Ile Pro Ile Leu Pro	Asp Val Glu Gln Phe	Trp		
	380		385		390
His Glu Arg Asp	Thr Val Pro Ser Val	Gln Asp Asn Asp Pro	Ile		
	395		400		405
Pro Trp Glu His	Glu Asp Gln Glu Thr	Gly Glu Gly Val Lys			
	410		415		

<210> 12

<211> 314

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472072CD1

<400> 12

Met Gly Asp Val	Asn Gln Ser Val Ala	Ser Asp Phe Ile Leu	Val
1	5	10	15
Gly Leu Phe Ser	His Ser Gly Ser Arg	Gln Leu Leu Phe Ser	Leu
	20	25	30
Val Ala Val Met	Phe Val Ile Gly Leu	Leu Gly Asn Thr Val	Leu
	35	40	45
Leu Phe Leu Ile	Arg Val Asp Ser Arg	Leu His Thr Pro Met	Tyr
	50	55	60
Phe Leu Leu Ser	Gln Leu Ser Leu Phe	Asp Ile Gly Cys Pro	Met
	65	70	75
Val Thr Ile Pro	Lys Met Ala Ser Asp	Phe Leu Arg Gly Glu	Gly
	80	85	90
Ala Thr Ser Tyr	Gly Gly Gly Ala Ala	Gln Ile Phe Phe Leu	Thr
	95	100	105
Leu Met Gly Val	Ala Glu Gly Val Leu	Leu Val Leu Met Ser	Tyr
	110	115	120
Asp Arg Tyr Val	Ala Val Cys Gln Pro	Leu Gln Tyr Pro Val	Leu
	125	130	135
Met Arg Arg Gln	Val Cys Leu Leu Met	Met Gly Ser Ser Trp	Val
	140	145	150
Val Gly Val Leu	Asn Ala Ser Ile Gln	Thr Ser Ile Thr Leu	His
	155	160	165
Phe Pro Tyr Cys	Ala Ser Arg Ile Val	Asp His Phe Phe Cys	Glu
	170	175	180
Val Pro Ala Leu	Leu Lys Leu Ser Cys	Ala Asp Thr Cys Ala	Tyr
	185	190	195
Glu Met Ala Leu	Ser Thr Ser Gly Val	Leu Ile Leu Met Leu	Pro
	200	205	210
Leu Ser Leu Ile	Ala Thr Ser Tyr Gly	His Val Leu Gln Ala	Val
	215	220	225
Leu Ser Met Arg	Ser Glu Glu Ala Arg	His Lys Ala Val Thr	Thr
	230	235	240
Cys Ser Ser His	Ile Thr Val Val Gly	Leu Phe Tyr Gly Ala	Ala
	245	250	255
Val Phe Met Tyr	Met Val Pro Cys Ala	Tyr His Ser Pro Gln	Gln
	260	265	270
Asp Asn Val Val	Ser Leu Phe Tyr Ser	Leu Val Thr Pro Thr	Leu


```

                275                280                285
Asn Pro Leu Ile Tyr Ser Leu Arg Asn Pro Glu Val Trp Met Ala
                290                295                300
Leu Val Lys Val Leu Ser Arg Ala Gly Leu Arg Gln Met Cys
                305                310

```

<210> 13
 <211> 254
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472074CD1

```

<400> 13
Met Ala Ser Arg Tyr Val Ala Val Gly Met Ile Leu Ser Gln Thr
  1          5          10          15
Val Val Gly Val Leu Gly Ser Phe Ser Val Leu Leu His Tyr Leu
  20          25          30
Ser Phe Tyr Cys Thr Gly Cys Arg Leu Arg Ser Thr Asp Leu Ile
  35          40          45
Val Lys His Leu Ile Val Ala Asn Phe Leu Ala Leu Arg Cys Lys
  50          55          60
Gly Val Pro Gln Thr Met Ala Ala Phe Gly Val Arg Tyr Phe Leu
  65          70          75
Asn Ala Leu Gly Cys Lys Leu Val Phe Tyr Leu His Arg Val Gly
  80          85          90
Arg Gly Val Ser Ile Gly Thr Thr Cys Leu Leu Ser Val Phe Gln
  95          100         105
Val Ile Thr Val Ser Ser Arg Lys Ser Arg Trp Ala Lys Leu Lys
  110         115         120
Glu Lys Ala Pro Lys His Val Gly Phe Ser Val Leu Leu Cys Trp
  125         130         135
Ile Val Cys Met Leu Val Asn Ile Ile Phe Pro Met Tyr Val Thr
  140         145         150
Gly Lys Trp Asn Tyr Thr Asn Ile Thr Val Asn Glu Asp Leu Gly
  155         160         165
Tyr Cys Ser Gly Gly Gly Asn Asn Lys Ile Ala Gln Thr Leu Arg
  170         175         180
Ala Met Leu Leu Ser Phe Pro Asp Val Leu Cys Leu Gly Leu Met
  185         190         195
Leu Trp Val Ser Ser Ser Met Val Cys Ile Leu His Arg His Lys
  200         205         210
Gln Arg Val Gln His Ile Asp Arg Ser Asp Leu Ser Pro Arg Ala
  215         220         225
Ser Pro Glu Asn Arg Ala Thr Gln Ser Ile Leu Ile Leu Val Ser
  230         235         240
Thr Phe Val Ser Ser Tyr Thr Leu Ser Cys Leu Phe Gln Val
  245         250

```

<210> 14
 <211> 362
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472077CD1

```

<400> 14
Met Tyr Lys Asp Cys Ile Glu Ser Thr Gly Asp Tyr Phe Leu Leu
  1          5          10          15
Cys Asp Ala Glu Gly Pro Trp Gly Ile Ile Leu Glu Ser Leu Ala
  20          25          30
Ile Leu Gly Ile Val Val Thr Ile Leu Leu Leu Leu Ala Phe Leu
  35          40          45

```

Phe	Leu	Met	Arg	Lys	Ile	Gln	Asp	Cys	Ser	Gln	Trp	Asn	Val	Leu	
				50					55					60	
Pro	Thr	Gln	Leu	Leu	Phe	Leu	Leu	Ser	Val	Leu	Gly	Leu	Phe	Gly	
				65					70					75	
Leu	Ala	Phe	Ala	Phe	Ile	Ile	Glu	Leu	Asn	Gln	Gln	Thr	Ala	Pro	
				80					85					90	
Val	Arg	Tyr	Phe	Leu	Phe	Gly	Val	Leu	Phe	Ala	Leu	Cys	Phe	Ser	
				95					100					105	
Cys	Leu	Leu	Ala	His	Ala	Ser	Asn	Leu	Val	Lys	Leu	Val	Arg	Gly	
				110					115					120	
Cys	Val	Ser	Phe	Ser	Trp	Thr	Thr	Ile	Leu	Cys	Ile	Ala	Ile	Gly	
				125					130					135	
Cys	Ser	Leu	Leu	Gln	Ile	Ile	Ile	Ala	Thr	Glu	Tyr	Val	Thr	Leu	
				140					145					150	
Ile	Met	Thr	Arg	Gly	Met	Met	Phe	Val	Asn	Met	Thr	Pro	Cys	Gln	
				155					160					165	
Leu	Asn	Val	Asp	Phe	Val	Val	Leu	Leu	Val	Tyr	Val	Leu	Phe	Leu	
				170					175					180	
Met	Ala	Leu	Thr	Phe	Phe	Val	Ser	Lys	Ala	Thr	Phe	Cys	Gly	Pro	
				185					190					195	
Cys	Glu	Asn	Trp	Lys	Gln	His	Gly	Arg	Leu	Ile	Phe	Ile	Thr	Val	
				200					205					210	
Leu	Phe	Ser	Ile	Ile	Ile	Trp	Val	Val	Trp	Ile	Ser	Met	Leu	Leu	
				215					220					225	
Arg	Gly	Asn	Pro	Gln	Phe	Gln	Arg	Gln	Pro	Gln	Trp	Asp	Asp	Pro	
				230					235					240	
Val	Val	Cys	Ile	Ala	Leu	Val	Thr	Asn	Ala	Trp	Val	Phe	Leu	Leu	
				245					250					255	
Leu	Tyr	Ile	Val	Pro	Glu	Leu	Cys	Ile	Leu	Tyr	Arg	Ser	Cys	Arg	
				260					265					270	
Gln	Glu	Cys	Pro	Leu	Gln	Gly	Asn	Ala	Cys	Pro	Val	Thr	Ala	Tyr	
				275					280					285	
Gln	His	Ser	Phe	Gln	Val	Glu	Asn	Gln	Glu	Leu	Ser	Arg	Asp	Lys	
				290					295					300	
Trp	Lys	Val	Leu	Leu	Asn	Ser	Asp	Phe	Leu	Ser	His	Ser	Gly	Ala	
				305					310					315	
Ala	Arg	Asp	Ser	Asp	Gly	Ala	Glu	Glu	Asp	Val	Ala	Leu	Thr	Ser	
				320					325					330	
Tyr	Gly	Thr	Pro	Ile	Gln	Pro	Gln	Thr	Val	Asp	Pro	Thr	Gln	Glu	
				335					340					345	
Cys	Phe	Ile	Pro	Gln	Ala	Lys	Leu	Ser	Pro	Gln	Gln	Asp	Ala	Gly	
				350					355					360	

Gly Val

<210> 15
 <211> 370
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472082CD1

<400> 15
 Met Cys Lys Cys Phe Arg Ser Gly Asn Ser Thr Pro Val Leu Cys
 1 5 10 15
 His Arg Asn Ser Glu Ala Trp Gln Pro Arg Lys Ala Pro Arg Thr
 20 25 30
 Gln Gln Thr Asp Met Gly Tyr Thr Asn Leu Asn Ser Lys Lys Glu
 35 40 45
 Cys Met Tyr Ile Lys Glu Asn Phe Lys Lys Thr Val Asp Lys Ile
 50 55 60
 Val Asp Pro Gly Asn His Ser Ser Val Thr Glu Ser Ile Leu Ala
 65 70 75
 Gly Leu Ser Glu Gln Pro Glu Leu Gln Arg Leu Phe Leu Leu
 80 85 90

Phe Leu Gly Ile Cys Val Val Thr Val Val Gly Asn Leu Gly Met
 95 100
 Ile Thr Leu Ile Gly Leu Ser Ser His Leu His Thr Pro Met Tyr
 110 115
 Tyr Phe Leu Ser Ser Leu Ser Phe Ile Asp Phe Cys His Ser Thr
 125 130
 Val Ile Thr Pro Lys Met Leu Val Asn Phe Ala Thr Glu Lys Asn
 140 145
 Ile Ile Ser Tyr Pro Glu Cys Met Ala Gln Leu Tyr Leu Phe Ser
 155 160
 Ile Phe Ala Ile Ala Glu Cys His Met Leu Ala Ala Met Ala Tyr
 170 175
 Asp Cys Tyr Val Ala Ile Cys Ser Pro Leu Leu Tyr Asn Val Ile
 185 190
 Met Ser Tyr His His Cys Phe Trp Leu Thr Val Gly Val Tyr Ile
 200 205
 Leu Gly Ile Leu Gly Ser Thr Ile His Thr Ser Phe Met Leu Arg
 215 220
 Leu Phe Leu Cys Lys Thr Asn Val Ile Asn His Tyr Phe Cys Asp
 230 235
 Leu Phe Pro Leu Leu Gly Leu Ser Cys Ser Ser Thr Tyr Ile Asn
 245 250
 Glu Leu Leu Val Leu Val Leu Ser Ala Phe Asn Ile Leu Met Pro
 260 265
 Ala Leu Thr Ile Leu Ala Ser Tyr Ile Phe Ile Ile Ala Ser Ile
 275 280
 Leu Arg Ile His Ser Thr Glu Gly Arg Ser Lys Ala Phe Ser Thr
 290 295
 Cys Ser Ser His Ile Leu Ala Val Ala Val Phe Phe Gly Ser Ala
 305 310
 Ala Phe Met Tyr Leu Gln Pro Ser Ser Val Ser Ser Met Asp Gln
 320 325
 Arg Lys Val Ser Ser Val Phe Tyr Thr Thr Ile Val Pro Met Leu
 335 340
 Asn Pro Leu Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Leu Ala
 350 355
 Val Lys Lys Ile Leu His Gln Thr Ala Cys
 365 370

<210> 16

<211> 319

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472128CD1

<400> 16

Met Thr Pro Gly Glu Leu Ala Leu Ala Ser Gly Asn His Thr Pro
 1 5 10
 Val Thr Lys Phe Ile Leu Gln Gly Phe Ser Asn Tyr Pro Asp Leu
 20 25 30
 Gln Glu Leu Leu Phe Gly Ala Ile Leu Leu Ile Tyr Ala Ile Thr
 35 40 45
 Val Val Gly Asn Leu Gly Met Met Ala Leu Ile Phe Thr Asp Ser
 50 55 60
 His Leu Gln Ser Pro Met Tyr Phe Phe Leu Asn Val Leu Ser Phe
 65 70 75
 Leu Asp Ile Cys Tyr Ser Ser Val Val Thr Pro Lys Leu Leu Val
 80 85 90
 Asn Phe Leu Val Ser Asp Lys Ser Ile Ser Phe Glu Gly Cys Val
 95 100 105
 Val Gln Leu Ala Phe Phe Val Val His Val Thr Ala Glu Ser Phe
 110 115 120
 Leu Leu Ala Ser Met Ala Tyr Asp Arg Phe Leu Ala Ile Cys Gln
 125 130 135

Pro	Leu	His	Tyr	Gly	Ser	Ile	Met	Thr	Arg	Gly	Thr	Cys	Leu	Gln	
				140					145					150	
Leu	Val	Ala	Val	Ser	Tyr	Ala	Phe	Gly	Gly	Ala	Asn	Ser	Ala	Ile	
				155					160					165	
Gln	Thr	Gly	Asn	Val	Phe	Ala	Leu	Pro	Phe	Cys	Gly	Pro	Asn	Gln	
				170					175					180	
Leu	Thr	His	Tyr	Tyr	Cys	Asp	Ile	Pro	Pro	Leu	Leu	His	Leu	Ala	
				185					190					195	
Cys	Ala	Asn	Thr	Ala	Thr	Ala	Arg	Val	Val	Leu	Tyr	Val	Phe	Ser	
				200					205					210	
Ala	Leu	Val	Thr	Leu	Leu	Pro	Ala	Ala	Val	Ile	Leu	Thr	Ser	Tyr	
				215					220					225	
Cys	Leu	Val	Leu	Val	Ala	Ile	Gly	Arg	Met	Arg	Ser	Val	Ala	Gly	
				230					235					240	
Arg	Glu	Lys	Asp	Leu	Ser	Thr	Cys	Ala	Ser	His	Phe	Leu	Ala	Ile	
				245					250					255	
Ala	Ile	Phe	Tyr	Gly	Thr	Val	Val	Phe	Thr	Tyr	Val	Gln	Pro	His	
				260					265					270	
Gly	Ser	Thr	Asn	Asn	Thr	Asn	Gly	Gln	Val	Val	Ser	Val	Phe	Tyr	
				275					280					285	
Thr	Ile	Ile	Ile	Pro	Met	Leu	Asn	Pro	Phe	Ile	Tyr	Ser	Leu	Arg	
				290					295					300	
Asn	Lys	Glu	Val	Lys	Gly	Ala	Leu	Gln	Arg	Lys	Leu	Gln	Val	Asn	
				305					310					315	
Ile	Phe	Pro	Gly												

<210> 17
 <211> 312
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472134CD1

<400> 17															
Met	Asp	Thr	Gly	Asn	Trp	Ser	Gln	Val	Ala	Glu	Phe	Ile	Ile	Leu	
1				5					10					15	
Gly	Phe	Pro	His	Leu	Gln	Gly	Val	Gln	Ile	Tyr	Leu	Phe	Leu	Leu	
				20					25					30	
Leu	Leu	Leu	Ile	Tyr	Leu	Met	Thr	Val	Leu	Gly	Asn	Leu	Leu	Ile	
				35					40					45	
Phe	Leu	Val	Val	Cys	Leu	Asp	Ser	Arg	Leu	His	Thr	Pro	Met	Tyr	
				50					55					60	
His	Phe	Val	Ser	Ile	Leu	Ser	Phe	Ser	Glu	Leu	Gly	Tyr	Thr	Ala	
				65					70					75	
Ala	Thr	Ile	Pro	Lys	Met	Leu	Ala	Asn	Leu	Leu	Ser	Glu	Lys	Lys	
				80					85					90	
Thr	Ile	Ser	Phe	Ser	Gly	Cys	Leu	Leu	Gln	Ile	Tyr	Phe	Phe	His	
				95					100					105	
Ser	Leu	Gly	Ala	Thr	Glu	Cys	Tyr	Leu	Leu	Thr	Ala	Met	Ala	Tyr	
				110					115					120	
Asp	Arg	Tyr	Leu	Ala	Ile	Cys	Arg	Pro	Leu	His	Tyr	Pro	Thr	Leu	
				125					130					135	
Met	Thr	Pro	Thr	Leu	Cys	Ala	Glu	Ile	Ala	Ile	Gly	Cys	Trp	Leu	
				140					145					150	
Gly	Gly	Leu	Ala	Gly	Pro	Val	Val	Glu	Ile	Ser	Leu	Ile	Ser	Arg	
				155					160					165	
Leu	Pro	Phe	Cys	Gly	Pro	Asn	Arg	Ile	Gln	His	Val	Phe	Cys	Asp	
				170					175					180	
Phe	Pro	Pro	Val	Leu	Ser	Leu	Ala	Cys	Thr	Asp	Thr	Ser	Ile	Asn	
				185					190					195	
Val	Leu	Val	Asp	Phe	Val	Ile	Asn	Ser	Cys	Lys	Ile	Leu	Ala	Thr	
				200					205					210	
Phe	Leu	Leu	Ile	Leu	Cys	Ser	Tyr	Val	Gln	Ile	Ile	Cys	Thr	Val	
				215					220					225	

```

Leu Arg Ile Pro Ser Ala Ala Gly Lys Arg Lys Ala Ile Ser Thr
230 235
Cys Ala Ser His Phe Thr Val Val Leu Ile Phe Tyr Gly Ser Ile
245 250
Leu Ser Met Tyr Val Gln Leu Lys Lys Ser Tyr Ser Leu Asp Tyr
260 265
Asp Gln Ala Leu Ala Val Val Tyr Ser Val Leu Thr Pro Phe Leu
275 280
Asn Pro Phe Ile Tyr Ser Leu Arg Asn Lys Glu Ile Lys Glu Ala
290 295
Val Arg Arg Gln Leu Lys Arg Ile Gly Ile Leu Ala
305 310

```

<210> 18
 <211> 321
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472136CD1

```

<400> 18
Met Asn Gln Thr Leu Asn Ser Ser Gly Thr Val Glu Ser Ala Leu
1 5 10 15
Asn Tyr Ser Arg Gly Ser Thr Val His Thr Ala Tyr Leu Val Leu
20 25 30
Ser Ser Leu Ala Met Phe Thr Cys Leu Cys Gly Met Ala Gly Asn
35 40 45
Ser Met Val Ile Trp Leu Leu Gly Phe Arg Met His Arg Asn Pro
50 55 60
Phe Cys Ile Tyr Ile Leu Asn Leu Ala Ala Ala Asp Leu Leu Phe
65 70 75
Leu Phe Ser Met Ala Ser Thr Leu Ser Leu Glu Thr Gln Pro Leu
80 85 90
Val Asn Thr Thr Asp Lys Val His Glu Leu Met Lys Arg Leu Met
95 100 105
Tyr Phe Ala Tyr Thr Val Gly Leu Ser Leu Leu Thr Ala Ile Ser
110 115 120
Thr Gln Arg Cys Leu Ser Val Leu Phe Pro Ile Trp Phe Lys Cys
125 130 135
His Arg Pro Arg His Leu Ser Ala Trp Val Cys Gly Leu Leu Trp
140 145 150
Thr Leu Cys Leu Leu Met Asn Gly Leu Thr Ser Ser Phe Cys Ser
155 160 165
Lys Phe Leu Lys Phe Asn Glu Asp Arg Cys Phe Arg Val Asp Met
170 175 180
Val Gln Ala Ala Leu Ile Met Gly Val Leu Thr Pro Val Met Thr
185 190 195
Leu Ser Ser Leu Thr Leu Phe Val Trp Val Arg Arg Ser Ser Gln
200 205 210
Gln Trp Arg Arg Gln Pro Thr Arg Leu Phe Val Val Val Leu Ala
215 220 225
Ser Val Leu Val Phe Leu Ile Cys Ser Leu Pro Leu Ser Ile Tyr
230 235 240
Trp Phe Val Leu Tyr Trp Leu Ser Leu Pro Pro Glu Met Gln Val
245 250 255
Leu Cys Phe Ser Leu Ser Arg Leu Ser Ser Ser Val Ser Ser Ser
260 265 270
Ala Asn Pro Val Ile Tyr Phe Leu Val Gly Ser Arg Arg Ser His
275 280 285
Arg Leu Pro Thr Arg Ser Leu Gly Thr Val Leu Gln Gln Ala Leu
290 295 300
Arg Glu Glu Pro Glu Leu Glu Gly Gly Glu Thr Pro Thr Val Gly
305 310 315
Thr Asn Glu Met Gly Ala
320

```

<210> 19
 <211> 316
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472142CD1

<400> 19
 Met Gln Gly Glu Asn Phe Thr Ile Trp Ser Ile Phe Phe Leu Glu
 1 5 10 15
 Gly Phe Ser Gln Tyr Pro Gly Leu Glu Val Val Leu Phe Val Phe
 20 25 30
 Ser Leu Val Met Tyr Leu Thr Thr Leu Leu Gly Asn Ser Thr Leu
 35 40 45
 Ile Leu Ile Thr Ile Leu Asp Ser Arg Leu Lys Thr Pro Met Tyr
 50 55 60
 Leu Phe Leu Gly Asn Leu Ser Phe Met Asp Ile Cys Tyr Thr Ser
 65 70 75
 Ala Ser Val Pro Thr Leu Leu Val Asn Leu Leu Ser Ser Gln Lys
 80 85 90
 Thr Ile Ile Phe Ser Gly Cys Ala Val Gln Met Tyr Leu Ser Leu
 95 100 105
 Ala Met Gly Ser Thr Glu Cys Val Leu Leu Ala Val Met Ala Tyr
 110 115 120
 Asp Arg Tyr Val Ala Ile Cys Asn Pro Leu Arg Tyr Ser Ile Ile
 125 130 135
 Met Asn Arg Cys Val Cys Ala Arg Met Ala Thr Val Ser Trp Val
 140 145 150
 Thr Gly Cys Leu Thr Ala Leu Leu Glu Thr Ser Phe Ala Leu Gln
 155 160 165
 Ile Pro Leu Cys Gly Asn Leu Ile Asp His Phe Thr Cys Glu Ile
 170 175 180
 Leu Ala Val Leu Lys Leu Ala Cys Thr Ser Ser Leu Leu Met Asn
 185 190 195
 Thr Ile Met Leu Val Val Ser Ile Leu Leu Leu Pro Ile Pro Met
 200 205 210
 Leu Leu Val Cys Ile Ser Tyr Ile Phe Ile Leu Ser Thr Ile Leu
 215 220 225
 Arg Ile Thr Ser Ala Glu Gly Arg Asn Lys Ala Phe Ser Thr Cys
 230 235 240
 Gly Ala His Leu Thr Val Val Ile Leu Tyr Tyr Gly Ala Ala Leu
 245 250 255
 Ser Met Tyr Leu Lys Pro Ser Ser Ser Asn Ala Gln Lys Ile Asp
 260 265 270
 Lys Ile Ile Ser Leu Leu Tyr Gly Val Leu Thr Pro Met Leu Asn
 275 280 285
 Pro Ile Ile Tyr Ser Leu Arg Asn Lys Glu Val Lys Asp Ala Met
 290 295 300
 Lys Lys Leu Leu Gly Lys Ile Thr Leu His Gln Thr His Glu His
 305 310 315
 Leu

<210> 20
 <211> 325
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472171CD1

<400> 20
 Met Glu Pro Leu Asn Arg Thr Glu Val Ser Glu Phe Phe Leu Lys
 1 5 10 15

Gly Phe Ser Gly Tyr Pro Ala Leu Glu His Leu Leu Phe Pro Leu
 20 25 30
 Cys Ser Ala Met Tyr Leu Val Thr Leu Leu Gly Asn Thr Ala Ile
 35 40 45
 Met Ala Val Ser Val Leu Asp Ile His Leu His Thr Pro Val Tyr
 50 55 60
 Phe Phe Leu Gly Asn Leu Ser Thr Leu Asp Ile Cys Tyr Thr Pro
 65 70 75
 Thr Phe Val Pro Leu Met Leu Val His Leu Leu Ser Ser Arg Lys
 80 85 90
 Thr Ile Ser Phe Ala Val Cys Ala Ile Gln Met Cys Leu Ser Leu
 95 100 105
 Ser Thr Gly Ser Thr Glu Cys Leu Leu Leu Ala Ile Thr Ala Tyr
 110 115 120
 Asp Arg Tyr Leu Ala Ile Cys Gln Pro Leu Arg Tyr His Val Leu
 125 130 135
 Met Ser His Arg Leu Cys Val Leu Leu Met Gly Ala Ala Trp Val
 140 145 150
 Leu Cys Leu Leu Lys Ser Val Thr Glu Met Val Ile Ser Met Arg
 155 160 165
 Leu Pro Phe Cys Gly His His Val Val Ser His Phe Thr Cys Lys
 170 175 180
 Ile Leu Ala Val Leu Lys Leu Ala Cys Gly Asn Thr Ser Val Ser
 185 190 195
 Glu Asp Phe Leu Leu Ala Gly Ser Ile Leu Leu Leu Pro Val Pro
 200 205 210
 Leu Ala Phe Ile Cys Leu Ser Tyr Leu Leu Ile Leu Ala Thr Ile
 215 220 225
 Leu Arg Val Pro Ser Ala Ala Arg Cys Cys Lys Ala Phe Ser Thr
 230 235 240
 Cys Leu Ala His Leu Ala Val Val Leu Leu Phe Tyr Gly Thr Ile
 245 250 255
 Ile Phe Met Tyr Leu Lys Pro Lys Ser Lys Glu Ala His Ile Ser
 260 265 270
 Asp Glu Val Phe Thr Val Leu Tyr Ala Met Val Thr Thr Met Leu
 275 280 285
 Asn Pro Thr Ile Tyr Ser Leu Arg Asn Lys Glu Val Lys Glu Ala
 290 295 300
 Ala Arg Lys Val Trp Gly Arg Ser Arg Ala Ser Ser Glu Gly Gly
 305 310 315
 Arg Gly Ser Val Gln Thr Gln Val Ser Gly
 320 325

<210> 21

<211> 313

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472172CD1

<400> 21

Met Gly Asn Trp Ser Thr Val Thr Glu Ile Thr Leu Ile Ala Phe
 1 5 10 15
 Pro Ala Leu Leu Glu Ile Arg Ile Ser Leu Phe Val Val Leu Val
 20 25 30
 Val Thr Tyr Thr Leu Thr Ala Thr Gly Asn Ile Thr Ile Ile Ser
 35 40 45
 Leu Ile Trp Ile Asp His Arg Leu Gln Thr Pro Met Tyr Phe Phe
 50 55 60
 Leu Ser Asn Leu Ser Phe Leu Asp Ile Leu Tyr Thr Thr Val Ile
 65 70 75
 Thr Pro Lys Leu Leu Ala Cys Leu Leu Gly Glu Glu Lys Thr Ile
 80 85 90
 Ser Phe Ala Gly Cys Met Ile Gln Thr Tyr Phe Tyr Phe Phe Leu
 95 100 105

Gly	Thr	Val	Glu	Phe	Ile	Leu	Leu	Ala	Val	Met	Ser	Phe	Asp	Arg	
				110					115					120	
Tyr	Met	Ala	Ile	Cys	Asp	Pro	Leu	His	Tyr	Thr	Val	Ile	Met	Asn	
				125					130					135	
Ser	Arg	Ala	Cys	Leu	Leu	Leu	Val	Leu	Gly	Cys	Trp	Val	Gly	Ala	
				140					145					150	
Phe	Leu	Ser	Val	Leu	Phe	Pro	Thr	Ile	Val	Val	Thr	Arg	Leu	Pro	
				155					160					165	
Tyr	Cys	Arg	Lys	Glu	Ile	Asn	His	Phe	Phe	Cys	Asp	Ile	Ala	Pro	
				170					175					180	
Leu	Leu	Gln	Val	Ala	Cys	Ile	Asn	Thr	His	Leu	Ile	Glu	Lys	Ile	
				185					190					195	
Asn	Phe	Leu	Leu	Ser	Ala	Leu	Val	Ile	Leu	Ser	Ser	Leu	Ala	Phe	
				200					205					210	
Thr	Thr	Gly	Ser	Tyr	Val	Tyr	Ile	Ile	Ser	Thr	Ile	Leu	Arg	Ile	
				215					220					225	
Pro	Ser	Thr	Gln	Gly	Arg	Gln	Lys	Ala	Phe	Ser	Thr	Cys	Ala	Ser	
				230					235					240	
His	Ile	Thr	Val	Val	Ser	Ile	Ala	His	Gly	Ser	Asn	Ile	Phe	Val	
				245					250					255	
Tyr	Val	Arg	Pro	Asn	Gln	Asn	Ser	Ser	Leu	Asp	Tyr	Asp	Lys	Val	
				260					265					270	
Ala	Ala	Val	Leu	Ile	Thr	Val	Val	Thr	Pro	Leu	Leu	Asn	Pro	Phe	
				275					280					285	
Ile	Tyr	Ser	Leu	Arg	Asn	Glu	Lys	Val	Gln	Glu	Val	Leu	Arg	Glu	
				290					295					300	
Thr	Val	Asn	Arg	Ile	Met	Thr	Leu	Ile	Gln	Arg	Lys	Thr			
				305					310						

<210> 22
 <211> 1413
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472033CB1

<220>
 <221> unsure
 <222> 176, 383, 927
 <223> a, t, c, g, or other

<400> 22
 atgaatcaga cggagcccgc ccagctggca gatgggggagc atctgagtgg atacgccagc 60
 agcagcaaca gcgtgcgcta tctggacgac cggcatccgc tggactacct tgacctgggc 120
 acggtgcacg cctcaacac cactgccatc aacacctcgg atctgaatga gactgngagc 180
 aggcgcgtgg acccggtgct tatcgatagg ttcttgagca acagggcggg ggacagcccc 240
 tggtagcaca tgctcatcag catgtacggc gtgctaatac tcttcggcgc cctaggcaac 300
 acccttgggt gttatagccc gtcacccgga agcccatcat gcgcactgct cgcaatctgg 360
 ttcatcctca acctggccat atncggccaa agcaagtgtg agtctcatcc gagcggactt 420
 tcagacctac ttttatgcct agtcaccatg ccgctgacct tgatggagat cctgtccaag 480
 tactggccct acggctcctg ctccatcctg tgcaaaacga ttgccatgct gcaggcactt 540
 tgtattttcg tgtcgacaat atccataacg gccattgcct tcgacagata tcagggtgatc 600
 gtgtacccca cgcgggacag cctgcagttc gtgggcccgc tgacgatcct ggccggggatc 660
 tgggcactgg cactgctgct ggctcgcgg ctgttcgtct acaaggagct gatcaacaca 720
 gacacgcggg cactcctgca gcagatcggc ctgcaggaca cgatcccgtg ctgcattgag 780
 gactggccaa gtcgcaacgg gcgcttctac tactcgatct tctcgctgtg cgtacaatac 840
 ctggtgcccc tcctgatcgt ctcggtggca tacttcggga tctacaacaa gctgaagagc 900
 cgcataccgg tgggtggtgt gcaggcncgg aaggtggagc gggggcggcg gatgaagcgc 960
 accaactgcc ttaacgtcag catcgccatc atctttggcg tttcttggtt gccgcttgac 1020
 tttttcaacc tgtacgcgga catggagcgc tcgcccgtca ctcagagcat gctagtccgc 1080
 tacgccatct gccacatgat cggcatgagc tccgcctgct ccaaccggtt gctctacggc 1140
 tggctcaacg acaacttccg taaagaaatt caagaactgc tctgccgttg ctcagacact 1200
 aatgtggtc ttaacgttca cagcacaggc aggcggcggc gcgcaggcgt 1260
 cgcaagtatg ggcgcggaat tctccaaagg cgaactcaag ctgctggggc aggcggcgcc 1320
 agagcggtag cgcggcgggg gaggcggtct ggcggccacc gacttcatga ccggcaccac 1380

gagggggggac tcgccaacat agttcatcat tga

1413

<210> 23

<211> 1076

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472034CB1

<400> 23

tctacccaaa	tgagaaggaa	cagagaaaca	attctggtaa	tattacaaaa	caaggttctt	60
taacacctcc	gaaggatcaa	accagctcac	cagcaatgga	tccaaaccaa	gatgaaatct	120
ctgaattacc	agaaaaagaa	ttcagaagat	caattattaa	gctgatcaaa	gaggcaccag	180
aaaaagggat	tccaggttta	gaggaaagcc	agcactggat	tgcactgccc	ctgggcatcc	240
tttacctcct	tgctttagtg	ggcaatgtta	ccattctctt	catcatctgg	atggacccat	300
ccttgcacca	atctatgtac	ctcttctctg	ccatgctagc	tgccatcgac	ctgggtctgg	360
cctcctccac	tgaccccaaa	gcccttgca	tgctcctggg	tcattgcccac	gagattgggt	420
acatcgctcg	cttgatccag	atgttcttca	tccatgcatt	ctcctccatg	gagtcagggg	480
tacttggtgg	catggctctg	gatcgctatg	tagccatttg	tcaccccttg	caccattcca	540
caatcctgca	tccaggggtc	atagggcgca	tccgaatggg	gggtgctggg	aggggattac	600
tactccttat	ccccttcccc	attttgttgg	gaacacttat	cttctgcca	gccaccatca	660
taggccatgc	ctattgtgaa	catatggctg	ttgtgaaact	tgctgtctca	gaaaccacag	720
tcaatcgagc	ttatgggctg	actatggcct	tgcttgtgat	tgggctggat	gttctggcca	780
ttgggtgttt	ctatgcccac	atcctccagg	cagtgtctgaa	ggtagccagg	agttagggcc	840
gacttaaggc	gtttagcaca	tgtggctctc	atatttgggt	catcctgggt	ttctatgtcc	900
ctggaatttt	ctccttcttc	actcaccgct	ttgggtcatca	tgtaccccat	catgtccatg	960
ttcttctggc	cacacgggat	ctcctcatgc	cacctgcgct	caatcctctt	gtctatggag	1020
tgaagactca	gcagatccgc	cagcgagtgc	tcagagtgtt	tacacaaaag	gattga	1076

<210> 24

<211> 948

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472035CB1

<400> 24

atggaaaccc	ctgcctcctt	cctccttgtg	gggtatcccag	gactgcaatc	ttcacatctt	60
tggctgggta	tctcactgag	tgccatgtac	atcatagccc	tgtaggaaa	caccatcatc	120
gtgactgcaa	tctggatgga	ttccactcgg	catgagccca	tgtattgctt	tctgtgtgtt	180
ctggctgctg	tggacattgt	tatggcctcc	tgggtgggtac	ccaagatggg	gagcatcttc	240
tgctcaggag	acagctcaat	cagctttagt	gcttgtttca	ctcagatgtt	ttttgtccac	300
ttagccacag	ctgtggagac	ggggctgctg	ctgaccatgg	cttttgaccg	ctatgtagcc	360
atctgcaagc	ctctacacta	caagagaatt	ctcagcctc	aagtatgct	gggaatgagt	420
atggccatca	ccatcagagc	tatcatagcc	ataactccac	tgagttggat	ggtgagtcac	480
ctacctttct	gtggctccaa	tgtggttgct	cactcctact	gtgagcacat	agctttggcc	540
agggttagcat	gtgctgaccc	cgtgcccagc	agtctctaca	gtctgattgg	ttcctctctt	600
atgggtggct	ctgatgtggc	cttcattgct	gcctcctata	tcttaattct	caaggcagta	660
tttggctctc	cctcaaagac	tgctcagttg	aaagcattaa	gcacatgtgg	ctcccatgtg	720
ggggttatgg	ctttgtacta	tctacctggg	atggcatcca	tctatgccc	ctgggtgggg	780
caggatgtag	tgcccttgca	cacccaagtc	ctgctagctg	acctgtacgt	gatcatccca	840
gccaccttaa	atcccatcat	ctatggcatg	aggaccaaac	aactgcggga	gagaatatgg	900
agttatctga	tgcattgtcct	ctttgaccat	tccaacctgg	gttcatga		948

<210> 25

<211> 945

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472036CB1

```

<400> 25
atgtcagcct ccaatatcac cttaacacat ccaactgcct tcttgttggt ggggattcca 60
ggcctggaac acctgcacat ctggatctcc atccctttct gcttagcata tacactggcc 120
ctgcttggaa actgcactct ccttctcatc atccaggctg atgcagccct ccatgaaccc 180
atgtacctct ttctggccat gttggcagcc atcgacctgg tcctttctct ctcagcactg 240
cccaaaatgc ttgccatatt ctggttcagg gatcgggaga taaacttctt tgccctgtctg 300
gcccagatgt tcttccttca ctccttctcc atcatggagt cagcagtgtc gctggccatg 360
gcctttgacc gctatgtggc tatctgcaag ccactgcact acaccaaggt cctgactggg 420
tccctcatca ccaagattgg catggctgct gtggcccggt ctgtgacact aatgactcca 480
ctccccttcc tgctgagatg tttccactac tgccgaggcc cagtgatcgc tcaactgtac 540
tgtgaacaca tggctgtggt gaggctggcg tgtggggaca ctagtctcaa caatatctat 600
ggcatcgctg tggccatggt tattgtggtg ttggacctgc tccttggtat cctgtcttat 660
atctttattc ttcaggcagt tctactgctt gcctctcagg aggcccgcta caaggcattt 720
gggacatgtg tctctcatat aggtgccatc ttagccttct acacaactgt ggtcatctct 780
tcagtcatgc accgtgtagc ccgccatgct gcccctcatg tccacatcct ccttgccaat 840
ttctatctgc tcttcccacc catggtcaat cccataatct atggtgtcaa gaccaagcaa 900
atccgtgaga gcatcttggg agtattccca agaaaggata tgtag 945

```

```

<210> 26
<211> 966
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 7472037CB1

```

```

<400> 26
atggctcatc aggcgcctga gaagcagcag gacaatggga cctggctggt gacagagttc 60
ctgctggtgg gattctccaa cctcccagaa ctgaggccca ctctcttcat cttgttccct 120
ctcacctacc tggtcacact cagtggcaat gccaccatca tcaccatcat ccagggtgat 180
cgcactctcc acacacctat gtaccgcttc ctggccgtgc tctccctctc tgagacctgc 240
tacacactgg tcaccatccc caatatgtcg gctcatctgc tgatggagag ccaggccatc 300
tccatcgagg gctgtcgggc ccagatgttc ttcttccctag gcttgggttg cagccattgt 360
ttcctcctta cctgatggg ctatgacagg tatgtggcca tctgccatcc cttgcgctac 420
tctgtgatca tgagaccac cgtctgctg tgtttgggag ccttggtttt cctgtctgtt 480
ttctcagttg ccttgattga gacctgcctg atcttctcct caccctctct tggcgcaggc 540
catgtggagc acttcttctg tgacattgcg cctgtgctga agctcagctg tgatgagagc 600
tcaactcaagg gacttggcat cttcttctct agcatcctcg tgggtgctgt ctccttccct 660
ttcattctcc tctcctacgc cttcattgtg gctgccattg tgaggatccc ttcggcctct 720
ggccggcgca aagccttctc tacctgcgga gccacactca cgggtggtcat cgtacatttt 780
ggttgtgcct ccatcatcta cctgagggcg gactctgggg ctaatccctc ccaggaccgc 840
ctggtggcgg tgttctacac cgtggtgaca ccgctgctga accctgtggt ttacaccctg 900
aggaacaagg aggtgagggg agcgtgagg aaaaacctgg cacggggctg tggagcattt 966
aagtaa

```

```

<210> 27
<211> 996
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 7472039CB1

```

```

<400> 27
atgagtcctg atgggaacca cagtagtgat ccaacagagt tcgtcctggc agggctccca 60
aatctcaaca gcgcaagagt ggaattatct tctgtgtttc ttcttgtcta tctcctgaat 120
ctgacaggca atgtgttgat tgtgggggtg gtaagggtcg atactcgact acagaccctt 180
atgtacttct ttctgggtaa cctgtcctgc ctgagagata tgctcacttc tgtcatcatt 240
ccaaagatgc tgagcaattt cctctcaagg caacacacta tttcctttgc tgcattgtat 300
acccaattct atttctactt ctttctcggt catctgtcat cctctgcgct accccttgct catgagtggg 420
tctgcggtac gctacctggc cttggcctgc tgggtggggg gactcgctcc tgtgttgg 480
gctgtgtgct ttctgttggt gcttcccttc tgttaagcagg gtgtgtggtt acagcacttc 540
cccacagtgg ctgtggcctt gctccgctcg gcttgcacca acaccaagaa gctggaggag 600
ttctgcgaca gtggcccact cctcgtcatt gtatcttctt tgetgatcac tgetgtgtcc 660
actgactttg tcttggcctc

```

tacggcctca	ttgtgctggc	agtectgagc	atccccctctg	cttcaggccg	tcagaaggcc	720
ttctctacct	gtacctccca	cttgatagtg	gtgacctctt	tctatggaag	tgccattttt	780
ctctatgtgc	ggccatcgca	gagtggttct	gtggacacta	actgggcagt	gacagtaata	840
acgacatttg	tgacaccact	gttgaatoca	ttcatctatg	ccttacgtaa	tgagcaagtc	900
aaggaagctt	tgaaggacat	gttttaggaag	gtagtggcag	gcgttttagg	gaatctttta	960
cttgataaat	gtctcagtga	gaaagcagta	aagtaa			996

<210> 28

<211> 1014

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472040CB1

<400> 28

atggggaacg	attctgtcag	ctacgagtat	ggggattaca	gcgacctctc	ggaccgccct	60
gtggactgcc	tggatggcgc	ctgcctggcc	atcgaccgcg	tgcgcgtggc	cccgctccca	120
ctgtatgccg	ccatcttcc	ggtgggggtg	ccgggcaatg	ccatgggtggc	ctgggtggct	180
gggaagggtg	cccgccggag	ggtgggtg	acctggttgc	tccacctggc	cgtggcggat	240
ttgctgtgct	gtttgtctct	gcccatacctg	gcagtgecca	ttgcccgtgg	aggccactgg	300
ccgtatgggt	cagtggcgtg	tcgggcgctg	ccctccatca	tctgtctgac	catgtatgcc	360
agcgtectgc	tcttggcagc	tctcagtggc	gaacctctgt	tcttggctct	cgggcctgcc	420
tggtggtcta	cggttcagcg	ggcgtgcggg	gtgcagggtg	cctgtggggc	agcctggaca	480
ctggccttgc	tgctcaccgt	gcccctccgc	atctaccgcc	ggctgcacca	ggagcacttc	540
ccagcccgcc	tgcagtgtgt	ggtggactac	ggcggtctct	ccagcaccga	gaatgcggtg	600
actgccatcc	gtttctttt	tggcttccctg	gggccccctg	tggccgtggc	cagctgccac	660
agtgcctctc	tgtgtggggc	agcccgaagc	tgcggccgcg	tgggcacagc	cattgtgggtg	720
gggttttttg	tctgtctggc	accctaccac	ctgctggggc	tggtgtctac	tgtggcggcc	780
ccgaactccg	cactcctggc	cagggccctg	cgggctgaac	ccctcatcgt	gggccttgcc	840
ctcgctcaca	gctgcctcaa	tcccattgctc	ttcctgtatt	ttgggagggc	tcaactccgc	900
cggctactgc	cagctgcctg	tcactgggccc	ctgagggagt	cccagggcca	ggacgaaagt	960
gtggacagca	agaaatccac	cagccatgac	ctggtctcgg	agatggaggt	gtag	1014

<210> 29

<211> 5122

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4250893CB1

<400> 29

gagccagcag	cccggggctc	cactctgggt	tctgaaagcc	cattccctgc	tctgcggctc	60
ctcccacccc	acctcttctc	agccttgcag	ctcaagggtt	gatctcagga	gtccaggacc	120
caggagaggg	aagaatctga	ggaacacaga	acagtgagcg	ttgcccacac	cccattctcc	180
gtcaccacat	ctcccctctg	taacaccctc	cctgcctggc	cctggacccc	atcccaggac	240
ctccctatca	gctgacttct	tccagtgtct	tgcaggcccc	tctgggctcc	tcctctccct	300
ggcttttctt	accactcccc	ctctatcggc	gtctatctgt	aggtgccctg	ggatttataa	360
aactgggttc	cgaatgctga	ataagagacg	gtaagagcca	aggcaaagga	cagcactgtt	420
ctctgcctgc	ctgataccct	caccacctgg	gaacatcccc	cagacaccct	cttaactccg	480
ggacagagat	ggttggcgga	gcctggggcc	gcctggcctg	ttacttggag	ttcctgaaga	540
aggaggagct	gaaggagttc	cagcttctgc	tcgcccaataa	agcgcactcc	aggagctctt	600
cgggtgagac	acccgctcag	ccagagaaga	cgagtggcat	ggaggtggcc	tcgtacctgg	660
tggctcagta	tggggagcag	cgggcctggg	acctagccct	ccatacctgg	gagcagatgg	720
ggctgaggtc	actgtgcgcc	caagcccagg	aaggggcagg	ccactctccc	tcattccctt	780
acagcccaag	tgaacccccc	ctgggggtctc	ccagccaacc	cacctccacc	gcagtgtctaa	840
tgccttggtg	tcataaattg	ccggcgggggt	gcaccacagg	ctcagagaga	agggttttga	900
gacagctgcc	tgacacatct	ggagcgcgct	ggagagaaaat	ctctgctcca	cacgtctacc	960
aagctcttcc	aagctcccca	gaccatgagt	ctccaagcca	ggagtcaccc	aacgccccca	1020
catccacagc	agtgtctggg	agctggggat	ccccacctca	gcccagccta	gcacccagag	1080
agcaggaggc	tcctgggacc	caatggcctc	tggatgaaac	gtcaggaatt	tactacacag	1140
aaatcagaga	aagagagaga	gagaaatcag	agaaaggcag	gccccatgg	gcagcgggtg	1200
taggaacgcc	cccacaggcg	cacaccagcc	tacagcccca	ccaccaccca	tgggagcctt	1260
ctgtgagaga	gagcctctgt	tccacatggc	cctggaaaaa	tgaggatttt	aacccaaaaa	1320

tcacacagct	gctactttcta	caaagacctc	accccagaag	ccaagatccc	ctgggtcaaga	1380
gaagctggcc	tgattatgtg	gaggagaatc	gaggacattt	aattgagatc	agagacttat	1440
ttggcccagg	cctggatacc	caagaacctc	gcatagtcat	actgcagggg	gctgctggaa	1500
ttgggaagtc	aacactggcc	aggcaggtga	aggaagcctg	ggggagaggc	cagctgtatg	1560
gggaccgctt	ccagcatgtc	ttctactttca	gctgcagaga	gctggcccag	tccaaggtgg	1620
tgagtctcgc	tgagctcatc	ggaaaagatg	ggacagccac	tccggctccc	attagacaga	1680
tcctgtctag	gccagagcgg	ctgctcttca	tcctcgatgg	tgtagatgag	ccaggatggg	1740
tcttgagga	gccgagttct	gagctctgtc	tcgactggag	ccagccacag	ccggcggatg	1800
cactgctggg	cagtttgctg	gggaaaacta	tacttcccga	ggcatccttc	ctgatcacgg	1860
ctcggaccac	agctctgcag	aacctcattc	cttcttttga	gcaggcacgt	tggttagagg	1920
tcctgggggt	ctctgagtc	agcaggaagg	aatattttcta	cagatatttc	acagatgaaa	1980
ggcaagcaat	tagagccttt	aggttgggtc	aatcaaacaa	agagctctgg	gccctgtgtc	2040
ttgtgccttg	ggtgtcctgg	ctggcctgca	cttgccctgat	gcagcagatg	aagcgggaagg	2100
aaaaactcac	actgacttcc	aagaccacca	caacctctctg	tctacattac	cttgcccagg	2160
ctctccaagc	tcagccattg	ggaccccagc	tcagagacct	ctgctctctg	gctgctgagg	2220
gcactctggca	aaaaaagacc	cttttcagtc	cagggaagcat	gggttagatg	gggttagatg	2280
gggccatcat	ctccaccttc	ttgaagatgg	gtattcttca	agagcacccc	atccctctga	2340
gctacagctt	cattcacctc	tgtttccaag	agttctttgc	agcaatgtcc	tatgtcttgg	2400
aggatgagaa	ggggagagggt	aaacatttcta	attgcatcat	agattttgaa	aagacgctag	2460
aagcatatgg	aatacatggc	ctggttgggg	catcaaacac	acgtttccta	ttgggcctgt	2520
ggaacctgat	gcagtggtgc	ccgtccctgc	acatctttca	ctgccggctg	tctcagggga	2580
ccctccactg	cttgatgag	actcgggaaca	agctgctgct	gcagccacac	tctctggagt	2640
tcgaagaaat	gggcatgtgt	gtagaacacg	aaacgttcc	gacacaagtg	atggcccatt	2700
ttaatctcag	ccgccacgtg	aagaaagcttc	acatggagct	cttagtggtc	actttctgca	2760
catggagccc	caccatggta	gtcctgttca	ggtgggtccc	agtcacagat	gcctattggc	2820
agattctctt	ctccgtcctc	aagggtcacca	gaaacctgaa	ggagctggac	ctaagtggaa	2940
actcgtctgag	ccactctgca	gtgaagagtc	tttgtaagac	cctgagacgc	cctcgtgccc	3000
tctgtgagac	cctggcgttg	gctggctgtg	gctcacagc	tgaggactgc	aaggaccttg	3060
cctttgggct	gagagccaac	cagaccctga	ccgagctgga	cctgagcttc	aatgtgctca	3120
cggatgctgg	agccaaaacac	cttttgccaga	gactgagaca	gccgagctgc	aagctacagc	3180
gactgcagct	ggctcagctg	ggcctcacgt	ctgactgctg	ccaggacctg	gcctctgtgc	3240
ttagtccag	ccccacgctg	aaggagctga	acctgcagca	gaaacaacctg	gatgacgttg	3300
gcgtgcgact	gctctgtgag	gggctcaggc	atcctgcctg	caaactcata	cgccctggggc	3360
tggaaccagac	aactctgagt	gatgagatga	ggcaggaact	gagggccctg	gagcaggaga	3420
aaacctcagct	gctcatcttc	agcagacgga	aaccaagtgt	gatgaccctc	actgagggcc	3480
tgatgacggg	agagcatagt	aatagcacat	cctcactcaa	gcggcagaga	ctcggatcag	3540
agagggcggc	ttcccatgtt	gctcaggcta	atctcaaact	cctggacgtg	agcaagatct	3600
tcccaattgc	tgagattgca	gaggaaaagct	ccccagaggt	agtaccggtg	gaactcttgt	3660
gcgtgccttc	tcctgcctct	caaggggacc	tgcatcacga	gcctttgggg	actgacgagt	3720
acttctgggg	ccccacgggg	cctgtggcta	ctgaggtagt	tgacaaagaa	aagaacttgt	3780
accgagttca	cttccctgta	gctggctcct	accgtggcc	caacacgggt	ctctgctttg	3840
tgatgagaga	agcggtgacc	ggtgagattg	aattctgtgt	gtgggaccag	ttcctgggtg	3900
agatcaaccc	acagcacagc	tggatgggtg	cagggcctct	gctggacatc	aaggctgagc	3960
ctggagctgt	ggaagctgtg	cacctccctc	actttgtggc	tctccaaggg	ggccatgtgg	4020
acacatccct	gttccaaatg	gcccacttta	aagaggaggg	gatgctcctg	gagaagccag	4080
ccagggtgga	gctgcatcac	atagtctctg	aaaaccccag	cttctccccc	ttgggagtc	4140
tcctgaaaat	gatccataat	gccctgcgct	tcattcccgt	cacctctgtg	gtgttgcttt	4200
accaccgct	ccatcctgag	gaagtcacct	tccacctcta	cctgatccca	agtgaactgt	4260
ccattcggaa	ggccatagat	gatctagaaa	tgaaattcca	gtttgtgcga	atccacaagc	4320
cacccccgct	gaccccactt	tatatgggct	gtcgttacac	tgtgtctggg	tctggttcag	4380
ggatgctgga	aatactcccc	aaggaaactg	agctctgcta	tcgaagccct	ggagaagacc	4440
agctgtttct	ggagtccctac	gttgccact	tgggatcagg	gatcaggctg	caagtgaag	4500
acaagaaaaga	tgagactctg	gtgtgggagg	ccttggtgaa	accaggagat	ctcatgcctg	4560
caactactct	gatccctcca	gcccgcatag	ccgtaccttc	acctctggat	gccccgcagt	4620
tgctgcactt	tgtggaccag	tatcgagagc	agctgatagc	ccgagtgaca	tcgggtggagg	4680
ttgtctttgga	caaactgcat	ggacaggtgc	tgagccagga	gcagtacgag	aggggtgctgg	4740
ctgagaacac	gaggcccagc	cagatgcgga	agctgttcag	cttgagccag	tcctggggacc	4800
ggaagtgcaa	agatggactc	taccaagccc	tgaaggagac	ccatcctcac	ctcattatgg	4860
aactctggga	gaagggcagc	aaaaagggac	tcctgcccact	cagcagctga	agtatcaaca	4920
ccagcccttg	acccttgagt	cctggctttg	gctgaccctt	ctttgggtct	cagtttcttt	4980
ctctgcaaac	aagttgccat	ctggtttgcc	ttccagcact	aaagtaatgg	aacttatgat	5040
gatgccttgc	tgggcattat	gtgtccagcc	agggatgcac	agggggccca	gtcaggtggg	5100
ctacagcatc	tcagggatgt	cc				5122

<210> 30

<211> 1241

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 6726656CB1

```
<400> 30
atztatggag gcaaccaaca aattacacag caatgaattc tggactgtag tcccacagcc 60
ttgagcctag atactagctg tgctactaat actctgtgtg accaggaagc ttgagtgcc 120
aagggtttga taaatgtgga aaataaccgc tggtcgaata tcctgttggc ctgctgtgat 180
gtgaggtgtg gaagaaacac gggagcagcc ttctcagga cactcttgt ttatctctct 240
agctctgaaa tcacatgaag ctgtggatgg agagtcacct gatagtccca gaaacccgtc 300
ccagcccaag gatgatgagt aaccagacgt tggtaaccga gttcatcctg cagggtcttt 360
cggagcacc agaataccgg gtgttcttat tcagctgttt cctcttcctc tactctgggg 420
ccctcacagg taatgtcctc atcaccttgg ccacacggtt caaccctggg ctccacgctc 480
ctatgtactt ttcttactc aacttggcta ctatggacat tatctgcacc tcttccatca 540
tgcccaaggc gctggccagt ctggtgtcgg aagagagctc catctcctac gggggctgca 600
tggccagctc ctatctctc acgtgggctg catcctcaga gctgctgctc ctacgggtca 660
tggcctatga ccggtacgca gccatctgcc acccgctgca ttacagcagc atgatgagca 720
aggtgttctg cagcgggctg gccacagccg tgtggtgct ctgcccgtc aacacggcca 780
tccacacggg gctgatgctg cgcttggatt tctgtggccc caatgtcatt atccatttct 840
tetgcgaggt cctccccctg ctgcttctct cctgcagctc cacctacgtc aacggtgtca 900
tgattgtcct ggcggtgct ttctacggca tagtgaactt cctgatgacc atcgctctct 960
atggcttcat cgtctccagc atcctgaagg tgaagactgc ctgggggagg cagaaagcct 1020
tctccacctg ctcttcccac ctacacgtgg tgtgcatgta ttacaccgct gtcttctacg 1080
cctacataag cccggtctct ggctacagcg caggaagag caagtgggt ggctgctgt 1140
acactgtgct gagtccctacc ctcaaccccc tcactatac ttgagaaac aaggagggtca 1200
aagcagccct caggaagctt ttccctttct tcagaaatta a 1241
```

<210> 31
<211> 1155
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472062CB1

```
<400> 31
atgaatgtcc ttctggcaga ttcaaattca aataaaaaga ttgtgcataa acacatctgc 60
agcctacagt cagcccccaa gactacgaac ctccaaccct caatatctga tatcctgcta 120
agtgttgaga gtaatgacag gaagaatgtg tctaagataa aaggggattg tttcaacaca 180
agagtatctt gtgattctaa aataacatcc atggagaata atacagaggt gagtgaattc 240
atcctgcttg gtctaacca tgccccagaa ctacaggttc cctctttat catgtttacc 300
ctcatctacc tcatcactct gactgggaac ctggggatga tcatattaat cctgctggac 360
tctcatctcc acactcccat gtactttttt ctgagtaacc tgtctcttgc aggcatgggt 420
tactctcag ctgtcactcc aaagggttta actgggttgc ttatagaaga caaagccatc 480
tcctacagtg cctgtgctgc tcagatgttc ttttgtgcag tctttgccac tgtggaaaat 540
tacctcttgt cctcaatggc ctatgaccgc tacgcagcag tgtgtaacct cctacattat 600
ttccaccaca tgacaacacg tgtgtgtgct tgtctggcta taggctgtta tgtcattgggt 660
ttctgtaatg cttctatcca aattggagat acatttcgcc tctctttctg catgtccaat 720
gtgattcatc actttttctg tgacaaacca gcagtcatta ctctgacctg ctctgagaaa 780
cacattagtg agttgattct tgttcttata tcaagtttta atgtcttttt tgcacttctt 840
gttaccttga ttctctatc gttcatattg atcaccattc ttaagaggca cacaggtaag 900
ggataccaga agcctttatc tacctgtggt tctcacctca ttgccatttt cttattttat 960
ataactgtca tcatcatgta catacgacca agttccagtc attccatgga cacagacaaa 1020
attgcatctg tgttctacac tatgatcatc cccatgctca gtcctatagt ctataccctg 1080
aggaacaaag acgtgaagaa tgcattcatg aaggttgttg agaaggcaaa atattctcta 1140
gattcagtct tttaa 1155
```

<210> 32
<211> 1260
<212> DNA
<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472067CB1

<400> 32

atgctggcag	ctgccttttg	agactctaac	tccagcagca	tgaatgtgtc	ctttgctcac	60
ctccactttg	ccggagggtg	cctgccctct	gattcccagg	actggagaac	catcatcccg	120
gctctcttgg	tggctgtctg	cctgggtggc	ttcgtgggaa	acctgtgtgt	gattggcatc	180
ctccttcaca	atgcttggaa	aggaaagcca	tccatgatcc	actccctgat	tctgaatctc	240
agcctggctg	atctctccct	cctgctgttt	tctgcaccta	tccgagctac	ggcgtactcc	300
aaaagtgttt	gggatctagg	ctggtttgtc	tgcaagtcct	ctgactgggt	tatccacaca	360
tgcatggcag	ccaagagcct	gacaatcggt	gtgggtggcca	aagtatgctt	catgtatgca	420
agtgaccag	ccaagcaagt	gagtatccac	aactacacca	tctggtcagt	gctgggtggc	480
atctggactg	tggctagcct	gttacccttg	ccggaatggt	tcttttagcac	catcaggcat	540
catgaagggtg	tggaaatgtg	cctcgtggat	gtaccagctg	tggctgaaga	gtttatgtcg	600
atgtttggta	agctctaccc	actcctggca	tttggccttc	cattattttt	tgccagcttt	660
tatttctgga	gagcttatga	ccaatgtaaa	aaacgaggaa	ctaagactca	aaatcctaga	720
aaccagatac	gctcaaagca	agtcacagtg	atgctgtctg	gcattgccat	catctctgct	780
ctcttgtggc	tccccgaatg	ggtagcttgg	ctgtgggtat	ggcatctgaa	ggctgcaggc	840
ccggcccccac	cacaagggtt	catagccctg	tctcaagtct	tgatgttttc	catctcttca	900
gcaaatectc	tcatttttct	tgtgatgtcg	gaagggttca	gggaaggctt	gaaaggtgta	960
tggaaatgga	tgataaccga	aaaacctcca	actgtctcag	agtctcagga	aacaccagct	1020
ggcaactcag	agggctcttc	tgacaagggt	ccatctccag	aatccccagc	atccatacca	1080
gaaaaagaga	aaccagctc	tccctcctct	ggcaaaggga	aaactgagaa	ggcagagatt	1140
cccacctctc	ctgacgtaga	gcagttttgg	catgagaggg	acacagtccc	ttctgtacag	1200
gacaatgacc	ctatccctg	ggaacatgaa	gatcaagaga	caggggaagg	tgttaaatag	1260

<210> 33

<211> 945

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472072CB1

<400> 33

atgggggatg	tgaatcagtc	ggtggcctca	gacttcattc	tgggtgggct	cttcagtcac	60
tcaggatcac	gccagctcct	cttctccctg	gtggctgtca	tgtttgtcat	aggccttctg	120
ggcaacaccg	ttcttctctt	cttgatccgt	gtggactccc	ggctccatac	acccatgtac	180
ttcctgtctc	gccagctctc	cctgtttgac	attggctgtc	ccatggtcac	catcccaag	240
atggcatcag	actttctgcg	gggagaaggt	gccacctcct	atggagggtg	tgcagctcaa	300
atattcttcc	tcacactgat	gggtgtggct	gagggcgctc	tgttggtcct	catgtcttat	360
gaccgttatg	ttgctgtgtg	ccagcccttg	cagtatcctg	tacttatgag	acgccaggta	420
tgtctgtctg	tgatgggctc	ctcctgggtg	gtagggtgtc	tcaacgcctc	catccagacc	480
tccatcaccc	tgcattttcc	ctactgtgcc	tcccgatttg	tggatcactt	cttctgtgag	540
gtgccagccc	tactgaagct	ctcctgtgca	gatacctgtg	cctacgagat	ggcgtgtgcc	600
acctcagggg	tgtctgactc	aatgtctcct	ctttccctca	tgcgccacct	ctacggccac	660
gtgtttgcagg	ctgtttctaag	catgcgctca	gaggaggcca	gacacaaggc	tgtcaccacc	720
tgtctctcgc	acatcacggg	agtggggctc	ttttatgggt	ccgcctgtgt	catgtacatg	780
gtgccttggc	cctaccacag	tccacagcag	gataacgtgg	tttccctctt	ctatagcctt	840
gtcaccccta	cactcaaccc	ccttatctac	agtctgagga	atccggagggt	gtggatgggt	900
ttggtcaaag	tgtcttagcag	agctggactc	aggcaaatgt	gctga		945

<210> 34

<211> 765

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472074CB1

<400> 34

atggcctccc	ggtatgtggc	agtgggaatg	atcttatcac	agaccgtggt	gggagtcctg	60
gggagcttct	ctgttcttct	ccattatctc	tccttttact	gcactgggtg	caggttaagg	120
tccacagatt	tgattgttaa	gcacctgatt	gtagccaact	tcttagctct	ccgctgtaaa	180
ggagtcccc	agacaatggc	agcttttggg	gttagatatt	ttctcaatgc	tcttgggtgc	240

```

aaacttggtt tctatctcca tagagtgggc aggggagtgt ccattggcac cacctgcctc 300
ttgagtgtct tccaggtgat cacggtcagc tccaggaaat ccaggtgggc aaaacttaaa 360
gagaaagccc ccaagcatgt tggtttttct gttctcctgt gctggatcgt gtgcatgttg 420
gtaaacatca tctttcccat gtatgtgact ggcaaatgga actacacaaa catcacagt 480
aacgaggatt tgggatactg tctctgggga ggcaacaaca aaatcgcaca gacactgcgt 540
gcaatgttgt tatcattccc tgatgtgttg tgtctggggc tcatgctctg ggtcagcagc 600
tccatggttt gcatcctgca caggcacaag cagcgggtcc agcacattga taggagcgat 660
ctctccccc gaggctcccc agagaacaga gctacgcaga gcatcctcat cctggtgagc 720
acctttgtgt cttcttacac tctctcctgc cttttccaag tttga 765

```

<210> 35
 <211> 1089
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472077CB1

```

<400> 35
atgtacaagg actgcatcga gtccactgga gactattttc ttctctgtga cgccgagggg 60
ccatggggca tcattctgga gtccctggcc atacttggca tcgtgggtcac aattctgcta 120
ctcttagcat ttctcttctt catgcgaaag atccaagact gcagccagtg gaatgtcctc 180
cccaccagc tcctcttctt cctgagtgtc ctggggctct tcggactcgc ttttgccttc 240
atcatcgagc tcaatcaaca aactgcccc gtacgctact ttctcttttg ggttctcttt 300
gctctctgtt tctcatgcct cttagctcat gcctccaatc tagtgaagct ggttcggggg 360
tgtgtctctt tctcctggac gacaattctg tgcattgcta ttggttgagc tctgttgcaa 420
atcattattg ccactgagta tgtgactctc atcatgacca gaggtatgat gtttgtgaat 480
atgacaccct gccagctcaa tgtggacttt gttgtactcc tgggtctatgt cctcttctct 540
atggccctca cattcttctg ctccaaagcc accttctgtg gcccggtgtg gaactggaag 600
cagcatggaa ggctcatctt tatcactgtg ctcttctcca tcatcatctg ggtggtgtgg 660
atctccatgc tcctgagagc caaccgcag tccagcgac agccccagtg ggagacccg 720
gtcgtctgca ttgctctggt caccaacgca tgggttttcc tgctgctgta catcgtccct 780
gagctctgca ttctctacag atcgtgtaga caggagtgcc ctttacaagg caatgcctgc 840
cccgtcacag cctaccaaca cagcttccaa gtggagaacc aggagctctc cagagataaa 900
tggaaggctt tactcaactc ggacttccca tcacacagtg gtgcagcccg agacagtgat 960
ggagctgagg aggatgtagc attaacttca tatggtactc ccattcagcc gcagactgtt 1020
gatccacac aagagtgttt catccacag gctaaactaa gccccagca agatgcagga 1080
ggagtataa 1089

```

<210> 36
 <211> 1334
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472082CB1

```

<400> 36
atgtgtaaat gcttcagaag tggcaatagc actccagtc tgtgtcaccg aaactcagaa 60
gcatggcagc ccaggaaggc cccaagaaca cagcaaactg acatgggtta caccaattta 120
aattccaaga aagagtgcac gtacattaag gaaaatttca aaaagactgt tgacaagatc 180
gtggaccctg gaaaccattc ctccagtact gactccattc tggctgggct ctccagaacag 240
ccagagctcc agctgcgcct ctctctctctg ttcttaggaa tctgtgtggt cacagtgggt 300
ggcaacttgg gcatgatcac actgattggg ctccagttctc acctgcacac acctatgtac 360
tatttctcta gcagtctgtc ctccattgac ttctgccatt ccactgtcat tacccttaag 420
atgctgggtg actttgcgac agagaagaac atcatctct acctgaatg catggctcag 480
ctctatttat tcagtatttt tgctattgca gagtgtcaca tgttggtgc aatggcgtat 540
gactgttatg ttgccatctg cagccccctg ctgtacaatg tcatcatgtc ctatcaccac 600
tgcttctggc tcacagtggg agttttacatt ttaggcatcc ttggatctac aattcatacc 660
agttttatgt tgagactctt tttgtgcaag actaatgtga ttaaccatta tttttgtgat 720
cttttccctc tcttggggct ctctgtctcc agcacctaca tcaatgaatt actggttctg 780
gtcttgagtg catttaacat cctgatgcct gccttaacca tccttgcttc ttacatcttt 840
atcattggca cctcctccg cattcactcc cttcagggca ggtccaaagc cttcagcact 900
tgcagctccc acatcttggc tgttgctgtt ttctttggat ctgcagcatt catgtacctg 960
cagccatcat ctgtcagctc catggaccag aggaaagtgt cgtctgtgtt ttatactact 1020

```

```

attgtgcccc tgctgaaccc cctgatctac agcctgagga ataaagatgt caaacttgcc 1080
gtgaagaaaa ttctgcatca gacagcatgt taatgaatag aatcaatggt atgttggttac 1140
atcaagatag gtcttttggt tgattagata tctaacttat tggatttatt gttgagattt 1200
atgaaaattt agtgatgctc ttttatgtaa cacctctcca aaatatctct cgggtctgct 1260
tccatcgaac ttatatcca atgagcatat gtaaagaaat acaaagaata aaatcaaaag 1320
acttttgagg tttt

```

<210> 37
 <211> 960
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472128CB1

```

<400> 37
atgacacctg gagaactagc ccttgccagt ggcaaccaca cccagtcac caagttcatc 60
ttgcagggat tctccaatta tccagacctc caggagcttc tcttcggagc catcctgctc 120
atctatgcc aacacagtgt gggcaacttg ggaatgatgg cactcatctt cacagactcc 180
catctccaaa gcccaatgta tttcttctc aatgtcctct cgtttcttga tatttggtac 240
tttctgtgg tcacacctaa gctcttggtc aacttctctg tctctgacaa gtccatctct 300
tttgagggct gtgtggtcca gctcgcttc tttgtagtgc atgtgacagc tgagagcttc 360
ctgctggcct ccattggccta tgaccgcttc cttagccatct gtcaaccctt ccattatggt 420
tctatcatga ccagggggac ctgtctccag ctggtagctg tgtctatgac atttggtgga 480
gccaaactcc ctatccagac tggaaaatgtc tttgccctgc ctttctgtgg gcccaaccag 540
ctaacacact actactgtga cataccacct cttctccacc tggcttctgtc caacacagcc 600
acagcaagag tggctcctta tgtcttttct gctctggtca cccttctgcc tgcctgcagc 660
attctcacct cctactgctt ggtcttggtg gccattggga ggatgcgctc agtagcaggg 720
agggagaagg acctctccac ttgtgcctcc cactttcttg ccattgccat tttctatggc 780
actgtggttt tcacctatgt tcagcccat ggatctacta acaataccaa tggccaagta 840
gtgtccgtct tctacacat cataattccc atgctcaatc ccttcatcta tagcctccgc 900
aacaaggagg tgaaggcgct tctgcagagg aagcttcagg tcaacatctt tcccggctga 960

```

<210> 38
 <211> 939
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472134CB1

```

<400> 38
atggacacag ggaactggag ccaggtagca gaattcatca tcttgggctt ccccatctc 60
cagggtgtcc agatttatct cttctctctg ttgcttctca tttacctcat gactgtgttg 120
ggaaacctgc tgatattcct ggtggtctgc ctggactccc ggcttcacac acccatgtac 180
cactttgtca gcattctctc cttctcagag cttggctata cagctgccac catccctaag 240
atgctggcaa acttgctcag tgagaaaaag accatttcat tctctgggtg tctcctgcag 300
atctatttct ttcaactcct tggagcgact gagtgctatc tcttgacagc tatggcctac 360
gataggatatt tagccatctg ccggcccttc cactacccaa cctcatgac cccaacactt 420
tgtgcagaga ttgccattgg ctgttggttg ggaggcttgg ctgggcccag agttgaaatt 480
tccttgattt cagcctccc attctgtggc cccaatcgca ttcagcacgt ctttctgtac 540
ttcctcctg tgetgagttt ggcttgcaat gatagctcta taaatgtcct agtagatttt 600
gttataaatt cctgcaagat cctagccacc ttctgtctga tctctgctc ctatgtgcag 660
atcatctgca cagtgtcag aattccctca gctgccggca agaggaaggc catctccacg 720
tgtgctctcc acttcaactg ggttctcctc ttctatggga gcatccttcc catgtatgtg 780
cagctgaaga agagctactc actggactat gaccaggccc tggcagtggt ctactcagtg 840
ctcacacct tcctcaacct cttcatctac agcttgcgca acaaggagat caaggaggct 900
gtgaggaggc agctaaagag aattgggata ttggcatga

```

<210> 39
 <211> 968
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472136CB1

<400> 39

```

ggatgaacca gactttgaat agcagtggga cegtggagtc agccctaacc tattccagag 60
ggagcacagt gcacacggcc tacctgggtg tgagctccct ggccatgttc acctgcctgt 120
gcgggatggc aggcaacagc atggtgatct ggctgctggg ctttcgaatg cacaggaacc 180
ccttctgcat ctatatcctc aacctggcgg cagccgacct cctcttcctc ttcagcatgg 240
cttcacagct cagcctggaa acccagcccc tgggtcaatac cactgacaag gtccacgagc 300
tgatgaagag actgatgtac tttgcctaca cagtgggcct gagcctgctg acggccatca 360
gcacccagcg ctgtctctct gtccctcttc ctatctgggt caagtgtcac cggcccaggc 420
acctgtcagc ctgggtgtgt ggctgtgctg ggacactctg tctcctgatg aacgggttga 480
cctcttcctt ctgcagcaag ttcttgaaat tcaatgaaga tcggtgcttc aggggtggaca 540
tgggtccaggc cgccctcatc atgggggtct taacccagat gatgactctg tccagcctga 600
ccctctttgt ctgggtgcgg aggagctccc agcagtggcg gcggcagccc acacggctgt 660
tcgtgtgggt cctggcctct gtccctgggt tcctcatctg tcccctgctc ctgagcatct 720
actggtttgt gctctactgg ttgagcctgc cgcccagatg gcaggtcctg tgcttcagct 780
tgtcacgcct ctccctgtcc gtaagcagca gcgccaaccc cgtcatctac ttcctgggtg 840
gcagccggag gagccacagg ctgcccacca ggtccctggg gactgtgctc caacaggcgc 900
ttcgcgaggc gcccagctg gaaggtgggg agacgccac cgtgggcacc aatgagatgg 960
gggcttga

```

<210> 40

<211> 1000

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472142CB1

<400> 40

```

attaaatgaa gggaatagta ctggaagaaa tatagatgaa agaaagaaaa tgcaaggaga 60
aaacttcacc atttgagca ttttttctt ggagggattt tcccagatcc cagggttaga 120
agtggttctc ttcgtcttca gccttgtaat gtatctgaca acgctcttgg gcaacagcac 180
tcttattttg atcactatcc tagattcacg ccttaaaacc cccatgtact tattccttgg 240
aaatctctct ttcattggata tttgttacac atctgcctct gtctctactt tgctggtgaa 300
cttgctgtca tcccagaaaa ccattatctt ttctgggtgt gctgtacaga tgtatctgtc 360
ccttgccatg ggctccacag agtgtgtgct cctggccgtg atggcatatg accgttatgt 420
ggccatttgt aaccgcgtga gatactccat catcatgaac aggtgcgtct gtgcacggat 480
ggccacggtc tctgggtga cgggttgctt gaccgctctg ctggaaacca gttttgccct 540
gcagataccc ctctgtggga atctcatcga tcaactcacg tgtgaaattc tggcgggtgt 600
aaagttagct tgcacaagtt cactgtctat gaacaccatc atgctgggtg tcagcattct 660
cctcttgcca attccaatgc tcttagtttg atctcttacc atcttcatcc tttccactat 720
cttgagaatc acctcagcag aggggaagaaa caaggctttt tctacctgtg gtgccatttt 780
gactgtgggt attttgtatt atggggctgc cctctctatg tacctaaagc cttcttcctc 840
aaatgcacaa aaaatagaca aaatcatctc gttgtcttac ggagtgtcta cccctatgtt 900
gaaccccata atttacagtt taagaaacaa ggaagtcaaa gatgctatga agaaattgtc 960
gggcaaaata acattgcatc aaacacagca acatctctga

```

<210> 41

<211> 1008

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472171CB1

<400> 41

```

ctgtggacca tctcttcaga actctgcagc atggagccgc tcaacagaac agaggtgtcc 60
gagttcttct tgaaaggatt ttctggctac ccagccctgg agcatctgct cttccctctg 120
tgctcagcca tgtacctggg gacctcctg gggaacacag ccatcatggc ggtgagcgtg 180
ctagatatcc acctgcacac gcccggtgac ttcttccctg gcaacctctc taccctggac 240
atctgttaca cgccacacct tgtgctctg atgctgggtc acctcctgtc atcccgaag 300
accatctcct ttgctgtctg tgccatccag atgtgtctga gcctgtccac gggctccacg 360
gagtgcctgc tactggccat caccgcctat gaccgctacc tggccatctg ccagccactc 420

```

```

aggtaaccacg  tgcctcatgag  ccaccgggctc  tgcgtgctgc  tgatgggagc  tgccctgggctc  480
ctctgcctcc  tcaagtcggg  gactgagatg  gtcattctcca  tgaggctgcc  cttctgtggc  540
caccacgtgg  tcagtcactt  cacctgcaag  atcctggcag  tgctgaagct  ggcatgcgcc  600
aacacgtcgg  tcagcgaaga  cttcctgctg  gcgggctcca  tcctgctgct  gcctgtacc  660
ctggcattca  tctgcctgtc  ctacttgctc  atcctggcca  ccacctgag  ggtgccctcg  720
gccgccaggt  gctgcaaagc  cttctccacc  tgcttgccac  acctggctgt  agtgctgctt  780
ttctacggca  ccattcatct  catgtacttg  aagcccaaga  gtaaggaagc  ccacatctct  840
gatgaggtct  tcacagtcct  ctatgccatg  gtcacgacca  tgctgaacc  caccatctac  900
agcctgagga  acaaggaggt  gaaggaggcc  gccagggaag  tgtggggcag  gagtcgggccc  960
tccagtgagg  gagggcgggg  ctctgtacag  acgcaggtct  caggttag  1008

```

<210> 42

<211> 972

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472172CB1

<400> 42

```

ggaaaccctg  cccaccatat  agtagttgtc  atgggaaact  ggagcactgt  gactgaaatc  60
accctaattg  ccttcccagc  tctcctggag  attcgaatat  ctctcttcgt  ggttcttgtg  120
gtaacttaca  cattaacagc  aacaggaaac  atcaccatca  tctccctgat  atggattgat  180
catcgctgc  aaactccaat  gtacttcttc  ctcaagtaatt  tgctctttct  ggatatctta  240
tacaccactg  tcattacccc  aaagtgtgtg  gcctgcctcc  taggagaaga  gaaaaccata  300
tcttttgctg  gttgcatgat  ccaaacatat  ttctacttct  ttctggggac  ggtggagttt  360
atcctcttgg  cgggtgatgt  ctttgaccgc  tacatggcta  tctgcgaccc  actgcactac  420
acggtcacga  tgaacagcag  ggcctgcctt  ctgctgggtc  tgggatgctg  ggtgggagcc  480
ttcctgtctg  tgttggttcc  aaccattgta  gtgacaaggc  taccttactg  taggaaagaa  540
attaatcatt  tcttctgtga  cattgcccct  cttcttcagg  tggcctgtat  aaatactcac  600
ctcattgaga  agataaaact  tctcctctct  gcccttgtea  tcctgagctc  cctggcattc  660
actactgggt  cctacgtgta  cataatttct  accatcctgc  gtatccccct  caccagggc  720
cgtcagaaag  ctttttctac  ctgtgcttct  cacatcactg  ttgtctccat  tgcccacggg  780
agcaacatct  ttgtgtatgt  gagaccat  cagaactcct  cactggatta  tgacaagggt  840
gccgctgtcc  tcatcacagt  ggtgaccct  ctctgaacc  cttttatcta  cagcttgagg  900
aatgagaagg  tacaggaagt  gttgagagag  acagtgaaca  gaatcatgac  cttgatacaa  960
aggaaaactt  ga  972

```

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number
WO 01/57085 A3

(51) International Patent Classification⁷: C07K 14/705,
16/28, C12N 5/10, C12Q 1/68, A61K 38/17, A01K
67/027, G01N 33/53

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics,
Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(21) International Application Number: PCT/US01/03455

(22) International Filing Date: 1 February 2001 (01.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/180,093 2 February 2000 (02.02.2000) US
60/182,045 11 February 2000 (11.02.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): INCYTE
GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo
Alto, CA 94304 (US).

Published:
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BAUGHN, Mariah,
R. [US/US]; 14244 Santiago Road, San Leandro, CA
94577 (US). AU-YOUNG, Janice [US/US]; 233 Golden
Eagle Lane, Brisbane, CA 94005 (US). YUE, Henry
[US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US).

(88) Date of publication of the international search report:
14 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/57085 A3

(54) Title: G-PROTEIN COUPLED RECEPTORS

(57) Abstract: The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/03455

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/705 C07K16/28 C12N5/10 C12Q1/68 A61K38/17
A01K67/027 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N C12Q A61K A01K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 23809 A (MERCK CO. INC.) 8 August 1996 (1996-08-08) SEQ ID NO:11; SEQ ID NO:12 page 14, line 1 - line 14; figures 5,6 page 15, line 15 -page 16, line 3 ---	1-19, 22-28
X	DATABASE EMBL [Online] Accession no. AC010111, 14 September 1999 (1999-09-14) MUNZY D.M. ET AL.: "Drosophila melanogaster clone RPC198-9B18, *** SEQUENCING IN PROGRESS ***," XP002175188 --- -/--	3

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 August 2001

Date of mailing of the international search report

16.11.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schönwasser, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/03455

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE SWALL [Online] Accession no. Q9VNM1, 1 May 2000 (2000-05-01) ADAMS M.D. ET AL.: "The genome sequence of Drosophila melanogaster; CG1147 PROTEIN" XP002175189</p> <p>---</p>	1
E	<p>WO 01 31005 A (PHARMACIA & UPJOHN CO) 3 May 2001 (2001-05-03)</p> <p>SEQ ID NO:3; SEQ ID NO:6</p> <p>---</p>	1,3, 6-10, 12-16, 18,19, 22-27
A	<p>DATABASE SWALL [Online] Accession no. 097505, 1 May 1999 (1999-05-01) ITO Y. ET AL.: "Sus scrofa NPY Y4 gene for neuropeptide Y receptor type 4, complete cds; NEUROPEPTIDE Y RECEPTOR TYPE 4 (NEUROPEPTIDE Y-FAMILY RECEPTOR Y4)" XP002175190</p> <p>-----</p>	1-19, 22-28

INTERNATIONAL SEARCH REPORT

Int. application No.
PCT/US 01/03455

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18 and 24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: **20,21 not searched;23,24 searched incompletely**
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-19,22-28 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-19,22-28 (all partially)

Invention 1:

An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1 or homologues or fragments thereof; an isolated polynucleotide encoding said polypeptide; a recombinant polynucleotide comprising a promoter sequence operably linked to said polynucleotide; a cell transformed with said recombinant polynucleotide; a transgenic organism comprising said recombinant polynucleotide; a method for producing said polypeptide; an isolated antibody which specifically binds to said polypeptide; an isolated polynucleotide comprising the polynucleotide sequence of SEQ ID NO:22 or homologues or complements thereof; methods for detecting a target polynucleotide in a sample, wherein said target polynucleotide has a sequence of above polynucleotide; a pharmaceutical composition comprising an effective amount of above polypeptide; a method for treating a disease or condition comprising administering said composition; methods for screening a compound for effectiveness as an agonist or antagonist of above polypeptide; a composition comprising an antagonist compound identified by said screening method, a method of treating a disease or condition comprising administering to a patient said composition; a method for screening for a compound that specifically binds to above polypeptide; a method of screening for a compound that modulates the activity of above polypeptide; a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises above isolated polynucleotide; a method for assessing toxicity of a test compound involving at least a fragment of above polynucleotide.

2. Claims: 1-19,22-28 (all partially)

Inventions 2-21:

Inventions no. 2-21 relate to subject-matter as defined above for "invention no. 1", with the exception, that each of the inventions refers to one of the polypeptide sequence of SEQ ID NO:2-SEQ ID NO:21 as mentioned in claim 1 (and to one of the corresponding nucleotide sequences SEQ ID NO:23-SEQ ID NO:42), but not to the polypeptide sequences SEQ ID NO:1 (or to the corresponding polynucleotide sequence SEQ ID NO:22).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 20,21 not searched;23,24 searched incompletely

Claims 20 and 21 refer to agonists identified by a method described in claim 19 without giving a true technical characterization of said agonists. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

Similarly, present claims 23 and 24 relate to antagonists identified by a method described in claim 19 by reference to a desirable characteristic or property, namely the property of being identifiable by a method as described in claim 22.

The claims cover all antagonists having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such antagonists. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antibodies against the polypeptide of claim 1 as antagonists for said polypeptides (please see page 40, line 32 - page 41, line 4).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/03455

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9623809	A	08-08-1996	US 5621079 A	15-04-1997
			CA 2212225 A1	08-08-1996
			EP 0809648 A1	03-12-1997
			JP 11500610 T	19-01-1999
			WO 9623809 A1	08-08-1996
			US 5939263 A	17-08-1999

WO 0131005	A	03-05-2001	AU 1218601 A	08-05-2001
			WO 0131005 A2	03-05-2001

Form PCT/ISA/210 (patent family annex) (July 1992)

